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Abstract 12 
ProTides comprise an important class of prodrugs currently marketed and developed as 13 
antiviral and anticancer therapies. The ProTide technology employs a phosphate masking 14 
groups capable of providing more favorable drug-like properties and an intracellular activation 15 
mechanism for enzyme-mediated release of a nucleoside monophosphate. Herein we describe 16 
the application of phosphoramidate chemistry to 1,3,4-O-acetylated N-acetylmannosamine 17 
(Ac3ManNAc) to deliver ManNAc-6-phosphate (ManNAc-6-P), a critical intermediate in sialic 18 
acid biosynthesis. Sialic acid deficiency is a hallmark of GNE myopathy, a rare congenital 19 
disorder of glycosylation (CDG) caused by mutations in GNE that limit the production of 20 
ManNAc-6-P. Synthetic methods were developed to provide a library of Ac3ManNAc-6-21 
phosphoramidates that were evaluated in a series of studies for their potential as a treatment 22 
for GNE myopathy. Prodrug 12b showed rapid activation in a carboxylesterase (CPY) 23 
enzymatic assay and favorable ADME properties, while also being more effective than 24 
ManNAc at increasing sialic acid levels in GNE-deficient cell lines than ManNAc. These 25 
2 
 
results provide a potential platform to address substrate deficiencies in GNE myopathy and 1 
other CDGs. 2 
  3 
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Introduction 1 
Congenital Disorders of Glycosylation (CDGs), first described as Carbohydrate Deficient 2 
Glycoprotein Syndrome by Jaeken et al. in 19801, are a group of rare, inherited, metabolic 3 
diseases characterized by defects in protein or lipid glycosylation. CDGs primarily affect 4 
children and can vary in clinical presentation from disabling to life-threatening conditions. 5 
Disease manifestations typically impact multiple organ systems, including liver and 6 
neurological involvement. Over 100 unique CDGs have been identified to date and the number 7 
continues to increase due to advances in the availability and efficiency of diagnostic 8 
techniques, namely genome sequencing.2, 3 9 
Among the CDGs, Hereditary Inclusion Body Myopathy (HIBM), also known as GNE 10 
myopathy (GNEM), is an autosomal recessive neuromuscular disorder characterized by 11 
symptoms that typically appear during the third decade of life, starting with skeletal muscle 12 
atrophy and weakness that slowly progresses to a significant physical disability. GNEM is 13 
caused by biallelic mutations in the GNE gene resulting in loss-of-function of uridine 5’-14 
diphosphate-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase and N-acetylmannosamine 15 
(ManNAc) kinase (GNE),4 a key enzyme in sialic acid biosynthesis (Figure 1).5 Sialic acids 16 
decorate cell surfaces as terminal component of glycoprotein and glycolipids,6 where they 17 
mediate or modulate a variety of physiological and pathological processes like signal 18 
transduction, cell adhesion, system embryogenesis, cancer metastasis or viral and bacterial 19 
infections.7 GNE is a bifunctional enzyme capable of catalyzing epimerization of UDP-20 
GlcNAc at the 2-position of the hexose ring to afford ManNAc and subsequent phosphorylation 21 
at the 6-position to afford ManNAc-6P (Figure 1). As the rate-limiting step in sialic acid 22 
biosynthesis, GNE deficiency results in decreased sialic acid production and consequent 23 
hyposialylation of glycoproteins, particularly in muscle tissue. The prevalence of GNEM is 24 
estimated to be roughly 1 to 9 in 1,000,000 people. More than 140 mutations in GNE have been 25 
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associated with GNE myopathy and can compromise the enzymatic activity of either catalytic 1 
domain.8 Each domain is functional when expressed separately, but evolution of some 2 
intramolecular dependency is exemplified by mutations causing reductions in both enzyme 3 
activities to different extents in a manner independent of domain localization.9 4 
 5 
 6 
Figure 1. Sialic acid biosynthetic cascade: the point of mutation of UDP-GlcNAc 2-7 
epimerase/ManNAc kinase, responsible for the GNE myopathy, is highlighted in yellow.  8 
To date, there is no approved therapy for GNEM.10 Palliative treatments, such as 9 
physiotherapy, analgesic drugs, mobility devices and psychological support are available to 10 
alleviate patient symptoms and improve quality of life. Therapeutic approaches have focused 11 
on substrate replacement paradigms seeking to re-establish available pools of intracellular 12 
5 
 
sialic acid by supplementation of aceneuramic acid (Neu5Ac) or its precursor, ManNAc.11 Both 1 
compounds have proven capable of restoring sialic acid biosynthesis and preventing or 2 
arresting disease progression in mouse models of GNEM.12 ManNAc is currently in late-stage 3 
clinical trials to assess its safety and efficacy in patients with GNE myopathy,13, 14 whereas 4 
aceneuramic acid, although safe and well-tolerated, failed to demonstrate efficacy in a Phase 3 5 
double-blind, placebo-controlled trial and was subsequently discontinued.15 Intravenous 6 
administration of immunoglobulin (IVIG) and gene therapy are other therapeutic options. 7 
Unfortunately, IVIG, although containing eight micromoles of sialic acid per gram, was not 8 
capable of improving muscle sialylation in GNE myopathy patients.10 Correction of GNE 9 
function through liposomal delivery of a wild-type GNE gene demonstrated increased 10 
production of sialic acid in vitro and in vivo. However, data supporting the continued 11 
stabilization of decline in muscle strength in a single patient are limited and no follow-up 12 
studies have been reported thus far.16 13 
Although ManNAc presents an intriguing therapeutic approach, poor intracellular transport and 14 
feedback inhibition necessitates high daily dosage (from 3g to 12g).13,17 No dose-response 15 
correlation was observed after repeated administration in patients with GNEM. Furthermore, 16 
patients with loss-of-function mutations in the ManNAc kinase domain of GNE may not be 17 
capable of phosphorylating ManNAc, thereby limiting restoration of sialic acid production. 18 
A study conducted in a GNE myopathy mouse model demonstrated that the lipophilic ManNAc 19 
analog O-tetra-acetylated N-acetylmannosamine (Ac4ManNAc) was more effective at 20 
increasing sialylation and preventing the myopathic phenotype when compared to natural sialic 21 
acid metabolites after oral administration.18 Ac4ManNAc is a prodrug of ManNAc and can 22 
more readily cross cellular membranes via passive diffusion, providing evidence that synthetic 23 
sugar analogs may be a practical consideration for the design of therapeutic agents for GNE 24 
myopathy. However, Ac4ManNAc still requires phosphorylation upon release of ManNAc. To 25 
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overcome the deficiency in both UDP-GlcNAc-2-epimerase and ManNAc kinase enzyme 1 
activity observed in GNE myopathy, administration of ManAc-6-P could be envisaged as an 2 
ideal substrate replacement strategy. Due to the high polarity of the phosphate moiety, a 3 
prodrug approach would be required to overcome poor cell permeability and mitigate de-4 
phosphorylation by extracellular phosphatases. 5 
Prodrug approaches for delivering phosphate carbohydrate analogs have been reported 6 
previously. Meyer et al designed cyclosaligenyl prodrugs of O-tetra-acetylated mannose-1-7 
phosphate19 whereas Eklund with co-workers synthesized two mannose-1-acetoxymethylated 8 
phosphates.20 Both classes of phosphate prodrugs were designed for the treatment of 9 
phosphomannomutase 2 (PMM2) deficiency, characteristic of the PMM2-CDG condition also 10 
known as CDG-Ia. Despite encouraging results demonstrating intracellular delivery of the 11 
mannose-1-monophosphate capable of correcting the CDG-Ia phenotype in vitro, these 12 
approaches were not explored further, most likely due to toxicity and stability concerns. To 13 
date, no additional studies have been reported. 14 
Our laboratory was previously successful in applying phosphoramidate chemistry to N-acetyl 15 
glucosamine for the treatment of osteoarthritis21, 22 and to various analogs of deoxyribose-1-16 
phosphate as potential anti-HIV agents.23 The N-acetylglucosamine phosphoramidate prodrugs 17 
generated in these studies showed acceptable biological stability and prodrug activation in 18 
chondrocyte cell lysate. In particular, the (L)-proline amino acid-containing O-3/O-4 19 
phosphoramidates demonstrated good activity at non-cytotoxic concentrations in human 20 
cartilage ex vivo, exceeding that of N-acetylglucosamine and emerging as promising candidate 21 
for further development for the treatment of osteoarthritis and other musculoskeletal diseases.  22 
Among many existing phosphate prodrug strategies,24 the ProTide approach has been 23 
successfully applied to nucleosides25, 26 as evidenced by the development and approval of the 24 
currently marketed drugs Sofosbuvir27 and Tenofovir Alafenamide (TAF)28 (Figure 2).  In 25 
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addition, in collaboration with our laboratories, NuCana plc is currently pioneering the ProTide 1 
technology in oncology, with the clinical candidates NUC-1031 (Acelarin),29 and NUC-3373,30 2 
respectively in Phase III and Phase I studies for patients with advanced solid tumors (Figure 3 
2). The phosphoramidate technology more recently was also exploited for the delivery of non-4 
nucleoside derivatives.31  5 
 6 
Figure 2. FDA-approved antiviral ProTides, Sofosbuvir and TAF and anticancer clinical 7 
candidates ProTides, NUC-1031 and NUC-3373. 8 
Given the importance of phosphoramidate prodrug technology in recent drug discovery, we 9 
revived our interest in its application toward the delivery of ManNAc-6-P as a novel approach 10 
to the treatment of GNE myopathy. Rationally designed ManNAc phosphoramidate prodrugs 11 
could enable the bypass of deficient GNE enzyme observed in GNEM patients by directly 12 
providing a source of intracellular ManNAc-6-P. Our approach sought to optimize drug-like 13 
properties of ManNAc phosphoramidates to improve upon the low permeability and plasma 14 
stability of ManNAc-6-P. In this work, we report the design, synthesis and evaluation of a 15 
family of ManNAc-6-P and Ac4ManNAc-6-P ProTide analogues, including ADME assays, 16 
enzymatic activation studies and in vitro assessment of sialic acid production in cell-based 17 
models of GNE myopathy. These data serve as proof-of-concept that the ProTide platform is a 18 
practical approach to substrate replacement therapies for GNE myopathy and potentially for 19 
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other CDGs characterized by deficiencies in phosphorylated metabolites. 1 
RESULTS AND DISCUSSION 2 
Chemistry 3 
Our synthetic efforts began with the synthesis of ManNAc-6-phosphoramidates. We initially 4 
envisaged the application of a synthetic procedure previously reported by our group for the 5 
preparation of glucosamine phosphoroamidates as feasible approach.21 Surprisingly, when 6 
ManNAc (1) was coupled with different phosphorochloridates in the presence of N-methyl 7 
imidazole (NMI),32 the formation of a complex mixture of by-products was always observed, 8 
from which no desired compound could be isolated. 9 
We then chose to explore an alternative synthetic route, involving protection of the anomeric 10 
hydroxyl prior to attempting the coupling reaction. The benzyl group was selected as the 11 
protecting group given its removal via hydrogenation is highly compatible with the 12 
phosphoramidate motif, as evidenced by a similar procedure employed by our group in the 13 
synthesis of N-acetylglucosamine phosphoramidate derivatives.22 14 
ManNAc (1) was fully acetylated (acetic anhydride in pyridine), and selectively benzylated at 15 
the anomeric position with benzyl alcohol and a catalytic amount of BF3OEt2. Subsequent O-16 
deprotection of the acetylated alcohols gave compound 2 as exclusively the -anomer in 87% 17 
yield over three steps (Scheme 1).33 Pleasingly, the coupling of phosphorochloridates (3a, 4a-18 
c) with compound 2 was efficient, affording exclusively O-6 phosphoramidate derivatives 5a 19 
and 6a-c (as a mixture of Sp and Rp diastereoisomers) with the same O-6 regioselectivity as 20 
previously observed for the N-acetyl glucosamine series.22 Finally, hydrogenation (10% Pd/C 21 
and H2) of compound 5a in methanol proceeded smoothly and after 12 hours both MS and 
1H-22 
NMR analysis of the crude reaction mixture revealed the presence of the desired product with 23 
concomitant disappearance of the starting material. Disappointingly, attempts to isolate pure 24 
compound 7a via traditional purification techniques (silica gel chromatography and/or reverse 25 
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phase HPLC) were unsuccessful due to partial degradation of the compound. When repeating 1 
the synthesis with phosphorochloridates bearing different promoieties, purification following 2 
hydrogenation consistently led to the observation of partial degradation and hindered isolation 3 
of the desired product. Surprised by these results, we decided to further investigate the 4 
degradation pathway via mass spectrometry. LC-MS analysis of 7a following purification 5 
indicated the presence of the desired compound (m/z 490) and a side product showing a peak 6 
at m/z 419 [M+Na]+ consistent with structure IV (Figure 3). Lack of UV absorbance in the LC-7 
MS traces for this peak and evidence of phenol release observed in the 1H-NMR spectra of the 8 
purified material further supported this hypothesis. LC-MS analysis of other 9 
phosphoramidates, whose purification was attempted after hydrogenation, led to similar results 10 
that indicated the formation of compound IV-like structures (m/z values were in agreement 11 
with the amino acid ester present in the parent compound). In addition, 31P-NMR of these 12 
mixtures showed two peaks at ~9 ppm, indicative of a chiral phosphorodiamidate as in 13 
compound IV (Figure 3). 14 
 15 
 16 
Scheme 1. Phosphoramidate synthesis through 1’-O-Bn-N-acetylmannosamine. aReagents and 17 
conditions: (i) Ac2O, DMAP, Py, rt, 12h; (ii) BnOH, BF3OEt2 cat., ACN, 80 °C, 3h; (iii) 18 
NaOMe cat. MeOH, rt, 5h; (iv) NMI, THF/pyridine 4/2 v/v, rt, 12h; (v) H2, 10% Pd/C, MeOH, 19 
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rt, 12h. 1 
A plausible mechanism for the formation of by-product IV is proposed in Figure 3. 2 
Deprotection of the benzyl group at the anomeric position leads to the formation of both - (I) 3 
and -anomers (III) in equilibrium with an open-chain form (II). Since the1-O-benzyl 4 
phosphoramidates were formed exclusively as  anomers and proved to be stable, we then 5 
hypothesized that only the  anomer of II could participate in the degradation pathway. The 6 
phosphorus atom of the  anomer could be particularly susceptible to intramolecular 7 
nucleophilic attack by the nitrogen atom of the sugar, leading to the corresponding cyclic 8 
adduct IV. Interestingly, this side reaction was not previously observed with any of the N-9 
acetyl-glucosamine phosphoroamidate derivatives.22 The difference in stereochemistry at the 10 
2’-position between GlcNAc and ManNAc phosphoramidates may be responsible for the 11 
divergence in reactivity toward the intramolecular cyclization process, further supporting the 12 
proposed mechanism. This could also justify the difficulty in obtaining the ManNAc 13 
phosphoramidate series from O-unprotected ManNAc in our earlier attempts. Although it 14 
would appear reasonable to assume that the phosphorous atom of the more flexible open chain 15 
structure II could undergo the same intramolecular nucleophilic attack by the nitrogen atom, 16 
we have ruled out this possibility given such degradation was not observed with N-acetyl 17 
glucosamine derivatives.22 Further studies to confirm this proposed mechanism are in progress. 18 
11 
 
  1 
Figure 3. Proposed mechanism for the formation of the side product IV during the purification 2 
step. 3 
Efforts to block the attack of the nucleophilic nitrogen atom onto the phosphorus center by 4 
introducing hindered amino acid esters in conjunction with bulkier aryloxy moieties failed and 5 
degradation was still observed. We then sought to stabilize the phosphoroamidate moiety by 6 
introducing a para-methoxy functionality within the aryl group, thereby decreasing the 7 
electrophilicity of the phosphorous atom and making it less susceptible to nucleophilic attack. 8 
This resulted in a decreased rate of by-product formation and enabled isolation of the desired 9 
products (8a-c) (Scheme 1). However, these compounds were not pursued further as possible 10 
candidates due to unsatisfactory ADME properties, namely poor cell permeability due to the 11 
presence of several free hydroxyl groups. 12 
Given these results, we turned our attention to the preparation of 1,3,4-O-triacetylated 13 
ManNAc-6-phosphoramidates, which we envisaged as targets with more appropriate drug-like 14 
properties. The acetyl protecting groups would further increase the lipophilicity of the 15 
compounds while allowing for the possibility of in vivo cleavage by plasma esterases following 16 
absorption from the gut, thus acting as a dual prodrug. Additionally, 1-O-acetylation could 17 
stabilize the prodrug structure and prevent the cyclization side-reaction. 1,3,4-O-triacetylated 18 
12 
 
ManNAc (11) was prepared according to a literature procedure34 outlined in Scheme 2. 1 
ManNAc (1) was tritylated, peracetylated and selectively deprotected at the O-6 position to 2 
yield compound 11 as a mixture of  and  anomers (1:0.3), which was then coupled with 3 
phosphorochloridates 3a-j in the presence of Grignard reagent32 to afford compounds 12a-j as 4 
a mixture of Sp and Rp diastereoisomers of  and  anomers. To avoid the formation of  5 
regioisomeric phosphoramidates arising from acetyl migration,35, 36 low reaction temperature 6 
was required during phosphoramidate formation. 7 
  8 
Scheme 2. Synthetic strategy for the preparation of 1,3,4-O-triacetylated ManNAc 9 
phosphoramidates. Reagents and conditions: (i) Pyridine, rt, 12h and 60 °C, 1h; (ii) Pyridine, 10 
0 °C to rt, 12h; (iii) glacial acetic acid, 60 °C, 2h; (iv) 1M t-BuMgCl, THF, 0 °C to rt, 12h. 11 
A small, rationally designed library of Ac3ManNAc phosphoramidates was built based on 12 
predicted log P values and existing knowledge of prodrug activation kinetics, using different 13 
amino acids and ester moieties to sample a diverse set of analogs (Table 1). Furthermore, since 14 
our previous report22 demonstrated that proline-based ProTides of N-acetyl glucosamine were 15 
particularly effective in cell-based models of osteoarthritis, we prepared the proline derivative 16 
12c. 17 
13 
 
Compound 
ID 
Ar R R1 R2 log Pa 
Yieldb 
(%) 
12a Ph CH3 iPr H 1.32 60 
12b Ph CH2CH(CH3)2 Et H 1.94 16 
12c Ph (CH2)3Pro Met H 0.92 19 
12d Naph H Met H 1.30 49 
12e Ph CH2Ph Et H 2.28 45 
12f Naph CH3 Bn H 2.95 47 
12g Ph CH(CH3)2 Bn H 2.64 39 
12h Ph CH3CH2CHCH3 Et H 1.95 34 
12i Ph CH3 Bn CH3 2.38 64 
12j Ph CH2CH(CH3)2 Bn H 3.04 61 
Table 2. Library of Ac3ManNAc phosphoramidate prodrugs. 
a Predicted log P calculated using 1 
SwissADME webservice.37 b Yield of the isolated compounds. 2 
Carboxypeptidase Activation Studies 3 
The ProTide technology has proven to be a valuable strategy capable of delivering membrane-4 
permeable nucleotide analogs intracellularly. Once across the cell membrane via passive 5 
diffusion, ProTides have been shown to undergo a series of enzymatic reactions leading to the 6 
release of the corresponding monophosphate analog. ManNAc phosphoramidates are believed 7 
to follow a similar activation sequence as depicted in Figure 4. 8 
14 
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Figure 4. Proposed enzymatic activation mechanism for Ac3ManNAc phosphoramidates: a) 2 
carboxylesterase or carboxypeptidase catalyzed ester hydrolysis to metabolite A. 3 
Intramolecular nucleophilic displacement of the aryloxy group provide the cyclic anhydride 4 
intermediate B. c) water-mediated hydrolysis of B to phosphoromonoamidate C. d) P-N bond 5 
cleavage mediated by HINT enzyme or by spontaneous hydrolysis. 6 
To assess whether a carboxypeptidase-mediated activation mechanism to 7 
phosphoromonoamidate C is also operative with ManNAc phosphoramidates, compounds 12a-8 
i (Scheme 2 and Table 2) were subjected to enzymatic studies by incubating each compound 9 
with carboxypeptidase Y (CPY, from Baker’s yeast) in 0.05 M Trizma buffer (pH = 7.6) in 10 
deuterated acetone, which allowed monitoring of reaction progress by 31P-NMR and LC-MS 11 
analyses. Almost all compounds showed activation of the promoiety with less than 50% of the 12 
parent phosphoramidates remaining 15 minutes following the addition of CPY. The only 13 
exception was 12c, which showed no activation (up to 24 hours). Figure 5 displays the 31P-14 
NMR spectra for the enzymatic activation assays of compounds 12b and 12c. Although the 15 
exact reaction sequence cannot be established from these data alone (and, consequently, the 16 
prodrug half-life), we can assert that compound 12b demonstrates rapid conversion into a 17 
species showing two signals at 6.82 and 7.02 ppm. On the other hand, replacement of leucine 18 
15 
 
with proline (12b to 12c) completely abolishes prodrug activation under identical incubation 1 
conditions, as the minor change from ethyl to methyl ester moiety at R1 is unlikely to cause 2 
such a stark contrast in susceptibility to carboxypeptidase-mediated activation. 3 
 4 
Figure 5. Deconvoluted 31P-NMR spectra of phosphoroamidates 12b (A) and 12c (B) over 5 
time after enzymatic incubation with Carboxypeptidase Y. Conditions: 202MHz, [D6]acetone, 6 
0.05M Trizma buffer, pH=7.6. 7 
Crude enzymatic reaction mixture of 12b was further analyzed by LC-MS confirming the 8 
presence of intermediate C (see Figure 31 in Supporting Information). To independently 9 
confirm the real structure of intermediate C (two 31P-NMR peaks at 6.82 and 7.02 ppm), a 10 
sample of this compound was prepared synthetically. Compound 12j was debenzylated via 11 
catalytic hydrogenation to the corresponding acid, which formed the expected intermediate C 12 
as a triethyl ammonium salt (13) (Scheme 3) after treatment with 0.1 M triethylammonium 13 
bicarbonate buffer. Comparison of LC-MS (tR = 2.5, 3.7 min) and 
31P-NMR (7.02, 6.97 ppm) 14 
data for compound 13 and those obtained from incubation of compound 12b confirmed the 15 
effective activation of 12b into the corresponding phosphoromonoamidate C. This result 16 
demonstrates for the first time that carbohydrate phosphoramidates undergo a similar activation 17 
pathway observed for nucleoside phosphoramidates. In addition, these studies suggest that 18 
16 
 
even non-nucleoside phosphoramidates are metabolized intracellularly and can serve as a 1 
substrate for monophosphate formation via enzymatic (i.e. HINT1) or spontaneous activation, 2 
but the selection of the appropriate amino acid side chain is critical towards enabling the 3 
activation mechanism. 4 
 5 
Scheme 3. Synthesis of compound 13. Reagents and conditions: (i) H2, 10% Pd/C, 6 
EtOH/EtOAc, 2h at rt; (ii) 0.1 M triethylammonium bicarbonate, 5 min at rt. 7 
ADME Evaluation 8 
Having established that these compounds can readily undergo enzymatic activation, we 9 
decided to evaluate several Ac3ManNAc phosphoramidates for ADME properties to select lead 10 
candidates for cell-based models of GNE myopathy.  11 
As previously mentioned, substrate replacement for GNE myopathy with highly polar small 12 
molecules were hampered by poor passive diffusion across cellular membranes. While the 13 
phosphoramidate promoiety increases cell permeability due to increased lipophilicity, this 14 
effect must be balanced with adequate aqueous solubility to ensure proper compound 15 
dissolution and absorption. Therefore, compounds 12b-e were screened for Caco-2 cell 16 
permeability, kinetic solubility, human plasma stability and metabolic stability as key 17 
parameters that would increase the likelihood of success in cell-based assays. The results of 18 
these studies are displayed in Table 3. 19 
17 
 
Compoun
d 
ID 
Papp (B-A/A-
B) 
(10-6 cm/s) 
Kinetic 
Solubility 
(μM, pH 7.4) 
Human Plasma 
Stability 
(% remaining at 2 h) 
HLM 
(T1/2, 
min) 
12b 0.8 / 1.5* 125 20 1.3 
12c 0.1 / 0.6* 152 15 1.4 
12d 0.3 / 0.6* 129 8.3 1.2 
12e 0.3 / 0.4* 124 9.8 0.8 
Table 3. ManNAc phosphoroamidates ADME properties. *with pgp/bcrp inhibitor GF120918 1 
(10 µM). Low permeability control was nadolol (Papp = 0.09) and high permeability control 2 
was metoprolol (Papp = 13.6). Efflux control was digoxin, and efflux ratio reduced from 374 to 3 
1.69 in the presence of GF120918. 4 
Compound 12b showed improved permeability based on the Caco-2 assay relative to all other 5 
compounds. Compound 12c had comparable permeability to 12d and 12e but showed increased 6 
plasma stability. Pleasingly, each compound showed acceptable solubility in aqueous 7 
environment at physiological pH. Hydrolysis of ester side chains via plasma esterases 8 
unsurprisingly causes rapid degradation of the parent compound, and the same phenomenon 9 
holds true for metabolic stability when incubated with human liver microsomes (HLMs) as 10 
evidenced by short half-lives of each compound. Aside from displaying acceptable ADME 11 
properties, 12c did not demonstrate activation in the aforementioned carboxypeptidase assay, 12 
potentially providing a negative control for assessing prodrug efficacy in cell-based assays 13 
models of GNE myopathy. Based on the results of the ADME screening, as well as the 14 
enzymatic activation data, compounds 12b and 12c were selected for further testing. 15 
Sialic Acid Quantification in Cell-Based Models of GNE Myopathy 16 
The evaluation of prodrugs (12b and 12c) to rescue sialic acid deficiencies in vitro was 17 
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conducted using two different cell lines: Lec3 CHO cells and GNEM patient-derived 1 
myoblasts. Both cell types present with reduced sialic acid levels due to mutations in GNE that 2 
mimic the hyposialylation defects observed in patients with GNE myopathy. In particular, Lec3 3 
mutant CHO cells lack any detectable GNE activity38, whereas the patient-derived myoblasts 4 
contained a D378Y mutation that cause an 80 % reduction in GNE activity.9 Compounds 12b 5 
and 12c were initially assessed for cytotoxicity in GNE mutant cell lines relative to ManNAc 6 
using Trypan Blue staining as an assay for cell viability after 48 hours incubation. At 0.1 mM, 7 
12b and 12c induced no observable difference in cell viability relative to controls and at 1 mM, 8 
cell viability was comparable to 1 mM ManNAc (see Supporting Info, Figure 32). 9 
Sialic acid quantification was then carried out in duplicate at two concentrations to assess dose-10 
response in GNE-deficient cells after 48-hour incubation with 0.1 mM and 1 mM 12b or 12c, 11 
1 and 100 mM for ManNAc, and a negative control with media only. We focused specifically 12 
on assessing total and free sialic acid production in membrane protein fractions, as sialic acid 13 
availability in cell membranes plays a key role in promoting muscle growth, structure and 14 
integrity, a critical issue for GNE myopathy patients. Although clinical studies with therapies 15 
like aceneuramic acid and ManNAc supplementation have shown increases in plasma sialic 16 
acid levels, it is not clear that these data have correlated with increases in sialic acid levels 17 
within tissues. 18 
As shown in Figure 6, 12b induced dose-dependent increases in total and free sialic acid levels 19 
in membrane protein fractions in both Lec3 CHO cells and GNEM patient-derived myoblasts. 20 
Given the lack of activation observed with 12c in the carboxypeptidase assay, the compound 21 
unsurprisingly produced no effects on sialic acid levels in Lec3 CHO cells. The effects of 12b 22 
were more pronounced than ManNAc, producing >30-fold and >50-fold more sialic acid in 23 
Lec3 CHO cell and GNEM patient-derived myoblasts, respectively, at 1 mM. 24 
19 
 
 1 
Figure 6. Sialic acid levels in membrane protein fraction. Sialic acid levels were determined 2 
using Sialic Acid Assay kit on isolated membrane protein fractions from Lec3 CHO cells (A) 3 
and GNEM patient-derived fibroblasts (B) incubated with 12b, 12c, ManNAc for 48 hours and 4 
normalized to control (media only) (n = 2, +/- SEM). 5 
CONCLUSION 6 
A substrate replacement paradigm was applied to the design of novel ProTide prodrugs of 7 
ManNAc-6-P as a therapeutic approach for GNE myopathy. A focused library of ManNAc-6-8 
P phosphoramidates was synthesized and evaluated for ADME properties to select lead 9 
compounds for profiling in cell-based models of GNE myopathy. Two leads, 12b and 12c, 10 
displayed the most promising ADME properties, although 12c did not show activation in a 11 
carboxypeptidase assay. The demonstration and independent confirmation of 12 
carboxypeptidase-mediated activation of 12b serves as the first example of a non-nucleoside 13 
phosphoramidate activation mechanism. The contrast in prodrug activation between 12b and 14 
12c further emphasizes the importance of selecting the appropriate amino acid side chain for 15 
the ProTide moiety. Compounds 12b and 12c were evaluated in two separate GNE-deficient 16 
cell lines for their ability to increase sialic acid production in membrane protein fractions 17 
20 
 
relative to ManNAc. Compound 12b produced >30-fold and >50-fold more sialic acid than 1 
ManNAc in Lec3 CHO cell and GNEM patient-derived myoblasts, respectively, at 1 mM. The 2 
extension of the ProTide platform to monosaccharide prodrugs presents an opportunity to 3 
explore therapeutic options for diseases due to the deficiency of sugar metabolites, such as the 4 
CDGs. 5 
Experimental Section 6 
General Experimental Information 7 
All chemicals were purchased from Sigma-Aldrich and Carbosynth and used without any 8 
further purification. All 1H-NMR (500MHz), 31P-NMR (202MHz) and 13C-NMR (125MHz) 9 
spectra were recorded on a Bruker AVANCE III HD 500 MHz spectrometer at 25 C. The 10 
deuterated solvent used were CDCl3 and CD3OD and the spectra were calibrated using their 11 
residual peaks: CDCl3, 
1H: =7.26 ppm; 13C: =77.36 ppm and CD3OD, 
1H: =3.34 ppm; 13C: 12 
=49.86 ppm. Chemical shifts () are reported in parts per million (ppm) and coupling 13 
constants (J) in Hertz. The following abbreviations are used in the assignment of NMR signals: 14 
s (singlet), d (doublet), t (triplet), q (quartet), spt (septet), m (multiplet), br (broad), dd (doublet 15 
of doublets) and ddd (doublet of doublet of doublets). The signals in the 1H and 13C NMR 16 
spectra were assigned based on analysis of coupling constants and additional two-dimensional 17 
experiments (COSY and HSQC). Some peaks in all NMR analyses may be overlapped. 18 
Reactions followed by thin-layer chromatography (precoated aluminium-backed plates, 60 19 
F254, 0.2 mm thickness, Merck, were visualized under short-wave ultraviolet light (254 nm) 20 
and/or via Pancaldi’s solution (molybdate ammonium cerium sulfate solution). 21 
Chromatography purifications were performed through ISOLERATM 3.0 BIOTAGE OS 852M 22 
both with the sample being loaded as a concentrated solution in the same eluent and pre-23 
adsorbed on top of silica. Fractions containing the product were identified by TLC, combined, 24 
21 
 
and the solvent was removed in vacuo. HPLC analysis was carried out to confirm the purity of 1 
final compounds by using a Varian Pursuit XRs 5 C18 150 mm  4.6 mm analytical column. 2 
All compounds tested had a purity of >95% as determined by HPLC at two different 3 
wavelengths (220 and 254 nm).  4 
Low-resolution mass and LC-MS analyses were performed on a Bruker Daltonics MicroTof-5 
LC instrument (atmospheric pressure ionization, electrospray mass spectroscopy) in either the 6 
positive- or negative-ion mode. MS parameters were optimized to the following: set capillary 7 
4500 V, set end plate offset -500 V, set nebulizer 1.0 Bar, set dry heater 200 ºC, set dry gas 8.8 8 
l/min, set divert valve source. Full scan mass spectra were recorded over a range of m/z 50-9 
3000.  10 
Standard Procedures. For practical purposes, standard procedures are given. Any variations 11 
from these procedures are discussed individually and described in full. 12 
Synthesis of ()-(2R,3S,4R,5S)-5-Acetamido-2-(acetoxymethyl)-6-(benzyloxy)tetrahydro-13 
2H-pyran-3,4-diyl diacetate (2): A solution of N-acetyl-D-mannosamine hydrochloride 14 
(45.21 mmol, 10.0 g) and DMAP (4.52 mmol, 0.55 g) in pyridine (200 mL) was reacted with 15 
acetic anhydride (43 mL) and stirred at rt for 12 h. The reaction mixture was diluted with DCM, 16 
washed with 1M HCl, NaHCO3 and brine. The residue was concentrated in vacuo and purified 17 
by column chromatography eluting with DCM/CH3OH (2:10) to afford tetra-acetylated-D-18 
mannosamine as a yellowish oil (74 %) which was then dissolved in ACN (40 mL) followed 19 
the addition of benzyl alcohol (57.8 mmol, 6 mL) and BF3
.Et2O (1.83 mmol, 230 L). The 20 
resulting mixture was heated at 80 C and stirred for 12 h. Afterwards, the mixture was cooled 21 
down to rt, diluted with DCM (400 mL) and washed with NaHCO3. The expected product was 22 
obtained after column chromatography purification eluted with Hexane/EtOAc (1:4) in 75 % 23 
yield. Final deacetylation was accomplished via treating the latter compound (2.29 mmol, 1.00 24 
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g) dissolved in anhydrous MeOH (50 mL) with a solution of NaOMe (0.23 mmol, 0.012 g) in 1 
300 L of dry CH3OH under argon atmosphere. The resulting solution was stirred at rt for 5 h 2 
and then Amberlite IR-120 hydrogen form was added leaving the mixture under stirring for 3 
another 1 h. The mixture was then filtered through celite and the solvent was removed under 4 
reduced pressure. The resulting solid was triturated with Et2O and further purified by column 5 
chromatography on silica using EtOAc/MeOH (4:1) to obtain the final product (2) in 87 % as 6 
two anomers  and  anomers (0.62 g). White solid. 1H-NMR (500 MHz, CDCl3): δH 7.35-7 
7.28 (m, 5H, Ph), 4.81 (s, 1H, H-1), 4.64 (d, 1H, J = 11.7 Hz, CH2aPh), 4.47-4.44 (m, 2H, 8 
CH2bPh and H-2), 4.11-4.09 (m, 1H, H-3), 3.95 (d, 1H, J = 10.8 Hz, H-4), 3.79-3.730 (m, 2H, 9 
H-5, H-6), 3.61 (d, 1H, J = 9.4 Hz, H-6), 2.00 (s, 3H, OCOCH3) ppm. MS (ES+): m/z 334.15 10 
[M+Na]+ 11 
Standard Procedure 1. General Synthesis of Phosphorochloridate (3a-i/4a-c): A solution 12 
of aryl dichlorophosphate (1 equiv) and an appropriate amino acid ester (1 equiv) in anhydrous 13 
DCM under argon atmosphere was cooled down to -78 C. Afterwards, Et3N (2 equiv) was 14 
added dropwise and the resulting mixture was stirred for 15 minutes at -78 C. Then, the 15 
reaction mixture was allowed to reach room temperature and left under stirring for 1 hour. The 16 
solvent was removed under reduced pressure, the solid residue was redissolved in diethyl ether 17 
and the resulting mixture was stirred under argon atmosphere for 20 min. The solid was filtered 18 
off and the solvent was evaporated giving the pure compound as a colorless oil which was used 19 
in the next step without further purification. 20 
Isopropyl (chloro(phenoxy)phosphoryl)-L-alaninate (3a): Colorless oil; 99 %, 8.36 g. 31P-21 
NMR (202 MHz, CDCl3, mixture of RP and SP diastereoisomers, a:b): δP 8.09 (1P), 7.71 (0.9) 22 
ppm. 1H-NMR (500 MHz, CDCl3): δH 7.39-7.36 (m, 2H, CH-Ph), 7.28-7.22 (m, 3H, CH-Ph), 23 
5.10-5.05 (m, 1H, CH(CH3)2), 4.16-4.08 (m, 1H, NHCHCO), 1.50 (dd, 3H, J = 2.4, 7.1 Hz, 24 
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NHCHCH3), 1.30-1.26 (m, 6H, CH(CH3)2) ppm. 1 
Ethyl (chloro(phenoxy)phosphoryl)-L-leucinate (3b): Prepared according to Standard 2 
procedure 1 in 98 %, yield as a mixture of two diastereoisomers (SSP and SRP). Colorless oil; 3 
4.20 g. 31P-NMR (202 MHz, CDCl3): δP 8.51 (1P), 8.27 (1P) ppm.
 1H-NMR (500 MHz, 4 
CDCl3): δH 7.38-7.34 (m, 2H, CH-Ph), 7.27-7.21 (m, 3H, CH-Ph), 4.34-4.19 (m, 3H, NH, 5 
OCH2CH3), 4.14-4.02 (m, 1H, NHCHCO), 1.86 (spt, 0.5H, J = 6.6 Hz, CHa(CH3)2), 1.79 (spt, 6 
0.5H, J = 6.6 Hz, CHb(CH3)2), 1.64-1.59 (m, 2H, CHCH2CH), 1.30-1.26 (m, 3 H, OCH2CH3), 7 
0.96-0.93 (m, 6H, CH3CHCH3) ppm. 8 
Methyl (chloro(phenoxy)phosphoryl)-D-prolinate (3c): Prepared according to Standard 9 
procedure 1 in 80 %, yield as a mixture of two diastereoisomers (SSP and SRP). Light yellow 10 
oil; 1.20 g. 31P-NMR (202 MHz, CDCl3): δP 7.95 (1P), 7.76 (0.9P) ppm.
 1H-NMR (500 MHz, 11 
CDCl3): δH 7.38-7.34 (m, 2H, CH-Ph), 7.30-7.28 (m, 1H, CH-Ph), 7.24-7.20 (m, 2H, CH-Ph), 12 
4.50-4.46 (m, 0.5H, NHCHaCO), 4.32-4.39 (m, 0.5H, NHCHbCO), 3.73 (s, 1.5H, COOCH3), 13 
3.72 (s, 1.5H, COOCH3), 3.58-3.49 (m, 2H, H-Pro), 2.28-2.19 (m, 1H, H-Pro), 2.15-2.08 (m, 14 
1H, H-Pro), 2.07-1.95 (m, 2H, H-Pro) ppm. 15 
Methyl (chloro(naphthalen-1-yloxy)phosphoryl)glycinate (3d): Prepared according to 16 
Standard procedure 1 in 78 %, yield as a mixture of two stereoisomers (SSP and SRP). Light 17 
yellow oil; 2.30 g. 31P-NMR (202 MHz, CDCl3): δP 9.08 ppm.
 1H-NMR (500 MHz, CDCl3): 18 
δH 8.06 (d, 1H, J = 8.3 Hz, CH-Naph), 7.87 (d, 1H, J = 7.7 Hz, CH-Naph), 7.72 (d, 1H, J = 8.3 19 
Hz, CH-Naph), 7.60-7.52 (m, 3H, CH-Naph), 7.43 (t, 1H, J = 8.3 Hz, CH-Naph), 4.43-4.40 20 
(br, 1H, NH), 4.00 (dd, 2H, J = 4.2, 9.7 Hz, NHCH2CO), 3.80 (s, 3H, COOCH3) ppm. 21 
Ethyl (chloro(phenoxy)phosphoryl)-L-phenylalaninate (3e): Prepared according to 22 
Standard procedure 1 in > 99 %, yield as a mixture of two diastereoisomers (SSP and SRP). 23 
Colorless oil; 6.30 g. 31P-NMR (202 MHz, CDCl3): δP 8.03 (1P), 7.96 (1P) ppm.
 1H-NMR (500 24 
MHz, CDCl3): δH 7.39-7.15 (m, 10H, CH-Ar), 4.48-4.35 (m, 1H, NHCHCO), 4.23-4.16 (m, 25 
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2H, OCH2CH3), 3.21-3.10 (m, 2H, CH2Ph), 1.26-1.21 (m, 3H, OCH2CH3) ppm. 1 
Benzyl (chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate (3f): Prepared according to 2 
Standard procedure 1 in 96 %, yield as a mixture of two diastereoisomers (SSP and SRP). 3 
Colorless oil; 7.2 g. 31P-NMR (202 MHz, CDCl3): δP 8.17 (0.8P), 7.90 (1P) ppm.
 1H-NMR 4 
(500 MHz, CDCl3): δH 8.06-8.04 (m, 1H, CH-Ar), 7.88-7.86 (m, 1H, CH-Ar), 7.74-7.72 (d, 5 
1H, J = 8.3 Hz, CH-Ar), 7.60-7.52 (m, 3H, CH-Ar), 7.44-7.40 (m, 1H, CH-Ar), 7.39-7.35 (m, 6 
2H, CH-Ar), 7.34-7.32 (m, 3H, CH-Ar), 5.23-5.15 (m, 2H, OCH2Ph), 4.52-4.39 (m, 1H, NH), 7 
4.37-4.31 (br, 1H, NHCHCO), 1.55 (dd, 3H, J = 7.3, 10.2 Hz, CHCH3) ppm. 8 
Benzyl (chloro(phenoxy)phosphoryl)-L-valinate (3g): Prepared according to Standard 9 
procedure 1 in 89 %, yield as a mixture of two diastereoisomers (SSP and SRP). Light yellow 10 
oil; 4.40 g. 31P-NMR (202 MHz, CDCl3): δP 9.53 (1P), 9.02 (1P) ppm.
1H-NMR (500 MHz, 11 
CDCl3): δH 7.38-7.22 (m, 10H, CH-Ar), 5.32-5.07 (AB system, 2H, J = 7.6 Hz, OCH2Ph), 12 
4.32-4.16 (m, 1H, NH), 4.04-3.93 (m, 1H, NHCHCO), 2.21-2.13 (m, 1H, 3H, CH(CH3)2), 1.00 13 
(m, 3H, CH(CH3)2), 0.90 (m, 3H, CH(CH3)2) ppm. 14 
Ethyl (chloro(phenoxy)phosphoryl)-L-isoleucinate (3h): Prepared according to Standard 15 
procedure 1 in 98 %, yield as a mixture of two diastereoisomers (SSP and SRP). Light yellow 16 
oil; 8.40 g. 31P-NMR (202 MHz, CDCl3): δP 9.47 (1P), 8.91 (0.9P) ppm.
 1H-NMR (500 MHz, 17 
CDCl3): δH 7.39-7.35 (m, 2H, CH-Ph), 7.29-7.22 (m, 3H, CH-Ph), 4.56-4.48 (m, 1H, NH), 18 
4.28-4.20 (m, 2H, OCH2CH3), 4.03-3.93 (m, 1H, NHCHCO), 1.91-1.88 (m, 1H, CH3CHCH2), 19 
1.56-1.48 (m, 1H, CHCH2aCH3), 1.30 (m, 3H, OCH2CH3), 1.27-1.23 (m, 1H, CHCH2bCH3), 20 
1.00-0.92 (m, 6H, CH(CH3)2) ppm. 21 
Benzyl 2-((chloro(phenoxy)phosphoryl)amino)-2-methylpropanoate (3i): Prepared 22 
according to Standard procedure 1 in 96 %, yield as a mixture of two stereoisomers (SSP and 23 
SRP). Light yellow oil; 96 %; 3.84 g. 
31P-NMR (202 MHz, CDCl3): δP 5.62 ppm.
 1H-NMR (500 24 
MHz, CDCl3): δH 7.28-7.11 (m, 10H, CH-Ph), 5.12 (s, 2H, OCH2Ph), 1.62 (s, 3H, C(CH3)2), 25 
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1.60 (s, 3H, C(CH3)2) ppm. 1 
Benzyl (chloro(phenoxy)phosphoryl)-L-leucinate (3j): Prepared according to Standard 2 
procedure 1 in > 99 %, yield as a mixture of two diastereoisomers (SSP and SRP). Colorless oil; 3 
2.43 g. 31P-NMR (202 MHz, CDCl3): δP 8.31 (0.9P), 8.00 (1P) ppm.
 1H-NMR (500 MHz, 4 
CDCl3): δH 7.30-7.26 (m, 7H, CH-Ar), 7.18-7.13 (m, 3H, CH-Ar), 5.16-5.08 (m, 2H, OCH2Ph), 5 
4.14-4.01 (m, 2H, NH and NHCHCO), 1.81-1.67 (m, 1H, CH(CH3)2), 1.61-1.49 (m, 2H, 6 
CHCH2CH), 0.88-0.85 (m, 6H, CH(CH3)2) ppm. 7 
Ethyl (chloro(4-methoxyphenoxy)phosphoryl)-L-leucinate (4a): Prepared according to 8 
Standard procedure 1 in > 99 %, yield as a mixture of two diastereoisomers (SSP and SRP). 9 
Colorless oil; 4.58 g. 31P-NMR (202 MHz, CDCl3): δP 9.03 (1P), 8.84 (1P) ppm.
 1H-NMR (500 10 
MHz, CDCl3): δH 7.18-7.16 (m, 2H, CH-Ph), 6.87-6.85 (m, 2H, CH-Ph), 4.22 (m, 2H, 11 
OCH2CH3), 4.15-4.00 (m, 2H, NH and NHCHCO), 3.78 (s, OCH3), 1.86 (spt, 0.5H, J = 6.7 12 
Hz, CHa(CH3)2), 1.79 (p, 0.5H, J = 6.7 Hz, CHb(CH3)2), 1.66-1.51 (m, 2H, CHCH2CH), 1.29 13 
(m, 3 H, OCH2CH3), 0.97-0.94 (m, 6H, CH(CH3)2) ppm. 14 
Methyl (chloro(4-methoxyphenoxy)phosphoryl)-D-prolinate (4b): Prepared according to 15 
Standard procedure 1 in > 99 %, yield as a mixture of two diastereoisomers (SSP and SRP). 16 
Light yellow oil; 10.00 g. 31P-NMR (202 MHz, CDCl3): δP 8.60 (1P), 8.42 (0.9P) ppm.
 1H-17 
NMR (500 MHz, CDCl3): δH 7.20 (dd, 1H, J = 1.8, 9.3 Hz, CH-Ph), 7.15 (dd, 1H, J = 1.8, 9.1 18 
Hz, CH-Ph), 6.86 (dd, 2H, J = 1.7 Hz, 8.9 Hz, CH-Ph), 4.49-4.45 (m, 0.5H, NHCHaCO), 4.41-19 
4.37 (m, 0.5H, NHCHbCO), 3.78 (s, 1.5H, OCH3), 3.77 (s, 1.5H, OCH3), 3.73 (s, 1.5H, OCH3), 20 
3.72 (s, 1.5H, OCH3), 3.57-3.49 (m, 2H, H-Pro), 2.2-2.18 (m, 1H, H-Pro), 2.15-2.07 (m, 1H, 21 
H-Pro), 2.06-1.94 (m, 2H, H-Pro) ppm. 22 
Isopropyl (chloro(4-methoxyphenoxy)phosphoryl)-L-alaninate (4c): Prepared according to 23 
Standard procedure 1 in > 99 %, yield as a mixture of two diastereoisomers (SSP and SRP). 24 
Colorless oil: 14.00 g. 31P-NMR (202 MHz, CDCl3): δP 8.76 (1P), 8.41 (1P) ppm.
 1H-NMR 25 
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(500 MHz, CDCl3): δH 7.19-7.16 (m, 2H, CH-Ph), 6.86 (dd, 2H, J = 2.4, 9.0 Hz, CH-Ph), 5.11-1 
5.04 (m, 1H, CH3CHCH3), 4.17-4.09 (m, 1H, NHCHCO), 3.78 (s, 3H, OCH3), 1.48 (dd, 3H, J 2 
= 3.7, 7.1 Hz, CH(CH3)2), 1.28-1.25 (m, 6H, CH(CH3)2) ppm. 3 
Standard Procedure 2. General Synthesis of 1-OBn-phosphoroamidates (5a/6a-c): To a 4 
solution of compound 2 (1 equiv) in THF/Py (8/2, v/v), N-methylimidazole (2.5 equiv) was 5 
added dropwise under argon atmosphere at room temperature and the resulting solution was 6 
stirred for 30 minutes. A solution of an appropriate phosphorochloridate (2.5 equiv) in THF 7 
was added dropwise to the mixture and stirred overnight at room temperature. After solvent 8 
evaporation, the product was purified by column chromatography on silica using DCM/ 9 
CH3OH (93:7) yielding the expected products 5-6. 10 
()-Isopropyl ((((2R,3S,4R,5S)-5-acetamido-6-(benzyloxy)-3,4-dihydroxytetrahydro-2H-11 
pyran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate (5a): Colorless oil; 45 %, 1.23 g. 31P-12 
NMR (202 MHz, CDCl3, mixture of RP and SP diastereoisomers as  anomer): δP 3.86 (1P), 13 
3.45 (0.6P) ppm. 1H-NMR (500 MHz, CDCl3): δH 7.37-7.15 (m, 10H, CH-Ar), 4.97-4.90 (m, 14 
1H, CH(CH3)2, overlap with the solvent), 4.78-4.77 (m, 1H, H-1, overlap with the solvent), 15 
4.67-4.63 (m, 1H, CH2aPh), 4.47-4.44 (m, 1H, CH2bPh), 4.35-4.30 (m, 1H, H-2), 4.01-3.90 (m, 16 
3H, NHCHCO, H-5 and H-4), 3.83-3.77 (m, 1H, H-3), 3.63-3.56 (m, 2H, H-6), 1.99 (s, 3H, 17 
NHCOCH3), 1.37-1.27 (m, 3H, NHCHCH3), 1.23-1.18 (m, 6H, CH(CH3)2) ppm. 
13C-NMR 18 
(125 MHz, MeOD): δC 174.63 (d, 
3JC-P= 5.2 Hz, C=O ester), 174.07 (d, 
3JC-P= 7.2 Hz, C=O 19 
ester), 170.03 (NHCOCH3), 154.66 (d, 
2JC-P= 6.8 Hz, “ipso” OPh), 152.28 (d, 
2JC-P= 6.5 Hz, 20 
“ipso” OPh), 138.57 (“ipso” OCH2Ph), 130.72, 130.69, 130.07, 129.41, 129.19, 129.16, 21 
128.85, 128.65, 126.03, 125.99, 123.82 (CHAr), 121.54 (d, 3JC-P= 4.9 Hz, CH-OPh), 121.45 22 
(d, 3JC-P= 4.9 Hz, CH-OPh), 99.57 (C-1), 73.12 (d, 
4JC-P= 6.8 Hz, C-4), 70.55, 70.39 (C-3), 23 
70.17 (OCH2Ph), 70.11, 70.03 (CH(CH3)2), 69.19, 69.07 (NHCHCO), 68.33 (C-5), 68.07 (d, 24 
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2JC-P= 5.6 Hz, C-6), 67.94 (d, 
2JC-P= 5.5 Hz, C-6), 54.35 (C-2), 21.98, 21.95 (NHCHCH3), 9.19, 1 
7.59 (CH(CH3)2) ppm. MS (ES+): m/z 603.22 [M+Na]
+ 2 
()-Ethyl ((((2R,3S,4R,5S)-5-acetamido-6-(benzyloxy)-3,4-dihydroxytetrahydro-2H-pyran-3 
2-yl)methoxy)(4-methoxyphenoxy)phosphoryl)-L-leucinate (6a): Prepared according to 4 
Standard procedure 2 in 20 %, yield as a mixture of RP and SP diastereoisomers as  anomer. 5 
Light yellow oil; 0.16 g. 31P-NMR (202 MHz, CDCl3): δP 4.37 (1P), 4.30 (1P) ppm.
 1H-NMR 6 
(500 MHz, CDCl3): δH 7.35-7.31 (m, 5H, CH-Ar), 7.18-7.13 (m 2H, CH-Ar), 6.87-6.83 (m, 7 
2H, CH-Ar), 4.79 (d, 1H, J = 10.9 Hz, H-1), 4.68-4.64 (m, 1H, CH2aPh), 4.49-4.41 (m, 1H, 8 
CH2bPh), 4.35-4.34 (m, 1H, H-2), 4.17-4.12 (m, 2H, OCH2CH3), 4.11-4.07 (m, 1H, H-4), 4.00-9 
4.07 (m, NHCHCO), 3.92-3.87 (m, 1H, H-3), 3.84-3.73 (m, 4H, OCH3 and H-5), 3.63-3.58 (m, 10 
2H, H-6), 2.01 (s, 3H, NHCOCH3), 1.71-1.62 (m, 1H, CH(CH3)2), 1.58-1.50 (m, 2H, 11 
CHCH2CH), 1.27-1.19 (m, 3H, OCH2CH3), 0.94-0.84 (m, 6H, CH(CH3)2) ppm. 
13C-NMR (125 12 
MHz, MeOD): δC 175.45 (d, 
3JC-P= 2.5 Hz, C=O ester), 175.33 (d, 
3JC-P= 2.5 Hz, C=O ester), 13 
174.11, 174.05 (NHCOCH3), 158.25, 157.59 (“ipso” PhOCH3), 145.83 (d, 
2JC-P= 3.8 Hz, 14 
“ipso” POPh), 138.56 (“ipso” OCH2Ph), 129.42, 129.39, 129.27, 129.22, 128.86, 122.46, 15 
122.42 (CHAr), 122.32 (d, 3JC-P= 4.4 Hz, CH-POPh), 122.18 (d, 
3JC-P= 4.5 Hz, CH-POPh), 16 
115.58, 115.55, 115.31 (CHAr), 99.56, 99.51 (C-1), 73.11 (d, 4JC-P= 7.5 Hz, C-4), 73.08 (d, 17 
4JC-P= 6.3 Hz, C-4), 70.58, 70.37 (NHCHCO), 70.14 (OCH2Ph), 68.40, 68.37 (C-5), 68.04 (d, 18 
2JC-P= 5.3 Hz, C-6), 67.88 (d, 
2JC-P= 5.4 Hz, C-6), 62.27, 62.22 (OCH2CH3), 56.02, 55.99 (C-19 
3), 54.56, 54.37 (C-2), 44.15, 43.96 (CHCH2CH), 25.55, 25.46 (CH(CH3)2), 23.19, 23.16, 20 
22.56, 22.41, 22.13, 21.90 (NHCOCH3 and CH(CH3)2) 14.46, 14.41 (OCH2CH3) ppm. MS 21 
(ES+): m/z 661.26 [M+Na]+ 22 
()-Methyl ((((2R,3S,4R,5S)-5-acetamido-6-(benzyloxy)-3,4-dihydroxytetrahydro-2H-pyran-23 
2-yl)methoxy)(4-methoxyphenoxy)phosphoryl)-D-prolinate (6b): Prepared according to 24 
28 
 
Standard procedure 2 in 32 %, yield as a mixture of RP and SP diastereoisomers as  anomer. 1 
Light yellow oil; 0.23 g. 31P-NMR (202 MHz, CDCl3): δP 2.27 (0.1P), 1.87 (1P) ppm.
 1H-NMR 2 
(500 MHz, CDCl3): δH 7.33-7.28 (m, 5H, CH-Ar), 7.14-7.12 (m 2H, CH-Ar), 6.87-6.84 (m, 3 
2H, CH-Ar), 4.77-4.76 (m, 1H, H-1), 4.61 (d, 1H, J = 11.7 Hz, CH2aPh), 4.55-51 (m, 1H, 4 
NHCHCO), 4.4 (m, 1H, J = 11.7 Hz CH2bPh), 4.33-4.31 (m), 4.26-4.23 (m), 3.98-3.95 (m), 5 
3.81-3.78 (m), 3.71 (s, 3H, COOCH3), 3.69 (s, 3H, PhOCH3), 3.41-3.33 (m), 2.19-2.13 (m, 2H, 6 
CH2Pro), 1.99 (s, 3H, NHCOCH3), 1.96-1.81 (m, 2H, CH2Pro) ppm. MS (ES+): m/z 631.21 7 
[M+Na]+ 8 
()-Isopropyl ((((2R,3S,4R,5S)-5-acetamido-6-(benzyloxy)-3,4-dihydroxytetrahydro-2H-9 
pyran-2-yl)methoxy)(4-methoxyphenoxy)phosphoryl)-L-alaninate (6c): Prepared according to 10 
Standard procedure 2 in 21 %, yield as a mixture of RP and SP diastereoisomers as  anomer. 11 
Colorless oil; 0.20 g. 31P-NMR (202 MHz, CDCl3): δP 4.30 (1P), 4.09 (0.8P) ppm.
 1H-NMR 12 
(500 MHz, CDCl3): δH 7.30 (m, 5H, CH-Ar), 7.14 (d, 2H, J = 86 Hz, CH-Ar), 6.84-6.80 (m, 13 
2H, CH-Ar), 4.98-4.93 (m, 1H, CH(CH3)2), 4.77 (s, 1H, H-1), 4.65-4.64 (m, 1H, CH2aPh), 14 
4.44-4.38 (m, 1H, CH2bPh), 4.32-4.31 (m, 1H, H-2), 4.29-4.21 (m), 3.98-3.95 (m), 3.93-3.88 15 
(m, 1H, NHCHCO), 3.80-3.77 (m), 3.70 (s, 1.5H, PhOCH3), 3.69 (s, 1.5H, PhOCH3), 3.62-16 
3.55 (m, 2H, H-6), 1.99 (s, 3H, NHCOCH3), 1.37-1.32 (m, 3H, NHCHCH3), 1.23-1.20 (m, 6H, 17 
CH(CH3)2) ppm. 
13C-NMR (125 MHz, MeOD): δC 173.34, 173.33 (C=O ester), 172.73, 172.67 18 
(NHCOCH3), 156.87 (“ipso” OPh), 144.38 (“ipso” POPh), 137.21 (“ipso” OCH2Ph), 128.05, 19 
127.87, 127.84, 127.49, 121.00, 120.93, 114.23, 114.20 (CHAr), 98.18, 98.14 (C-1), 73.11 (d, 20 
4JC-P= 7.5 Hz, C-4), 73.08 (d, 
4JC-P= 6.3 Hz, C-4), 70.58, 70.37 (NHCHCO), 70.14 (OCH2Ph), 21 
68.40, 68.37 (C-5), 68.04 (d, 2JC-P= 5.3 Hz, C-6), 67.88 (d, 
2JC-P= 5.4 Hz, C-6), 62.27, 62.22 22 
(OCH2CH3), 56.02, 55.99 (C-3), 54.56, 54.37 (C-2), 44.15, 43.96 (CHCH2CH), 25.55, 25.46 23 
(CH(CH3)2), 23.19, 23.16, 22.56, 22.41, 22.13, 21.90 (NHCOCH3 and CH(CH3)2) 14.46, 14.41 24 
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(OCH2CH3) ppm. MS (ES+): m/z 661.26 [M+Na]
+ 1 
Standard Procedure 3. General Synthesis of Deprotected Phosphoroamidates (8a-c): To a 2 
solution of 5 or 6 (1 equiv) in EtOH/EtOAc (2:1) was added Pd/C (10% Pd on activated carbon) 3 
under inert atmosphere. The resulting mixture was stirred at room temperature for 5 hours 4 
under H2 atmosphere (1 atm, ballon). The crude was filtered through celite, concentrated in 5 
vacuo and triturated with Et2O giving the expected products 8a-c. 6 
Ethyl ((((2R,3S,4R,5S)-5-acetamido-3,4,6-trihydroxytetrahydro-2H-pyran-2-yl)methoxy)(4-7 
methoxyphenoxy)phosphoryl)-L-leucinate (8a): Light yellow oil; 29%; 0.17 g. 31P-NMR (202 8 
MHz, CDCl3, mixture of RP and SP diastereoisomers as  and  anomers): δP 4.41 (1P), 4.31 9 
(0.7P), 4.19 (0.7P) ppm. 1H-NMR (500 MHz, CDCl3): δH 7.14 (d, 2H, J = 9.0 Hz, CH-Ar), 6.87 10 
(d, 2H, J = 9.0 Hz, CH-Ar), 5.03 (s, 1H, H-1), 4.56 (s, 1H, H-2), 4.34-4.26 (m, 1H, CH2Ph), 11 
4.17-4.12 (m, 2H, OCH2CH3), 4.11-4.07 (m, 1H, H-4), 4.00-4.07 (m, NHCHCO), 3.92-3.87 12 
(m, 1H, H-3), 3.84-3.73 (m, 4H, OCH3 and H-5), 3.63-3.58 (m, 2H, H-6), 2.01 (s, 3H, 13 
NHCOCH3), 1.71-1.62 (m, 1H, CH(CH3)2), 1.58-1.50 (m, 2H, CHCH2CH), 1.27-1.19 (m, 3H, 14 
OCH2CH3), 0.94-0.84 (m, 6H, CH(CH3)2) ppm. 
13C-NMR (125 MHz, MeOD): δC 174.20, 15 
174.09 (C=O ester), 172.77, 172.69 (NHCOCH3), 156.92, 156.84 (“ipso” PhOCH3), 144.41 (d, 16 
2JC-P= 6.8 Hz, “ipso” POPh), 121.06, 121.02, 120.81, 120.77, 114.21, 114.16 (CHAr), 93.67, 17 
93.37 (C-1), 73.11 (d, 4JC-P= 7.5 Hz, C-4), 73.08 (d, 
4JC-P= 6.3 Hz, C-4), 70.58, 70.37 18 
(NHCHCO), 70.14 (OCH2Ph), 68.40, 68.37 (C-5), 68.04 (d, 
2JC-P= 5.3 Hz, C-6), 67.88 (d, 
2JC-19 
P= 5.4 Hz, C-6), 62.27, 62.22 (OCH2CH3), 56.02, 55.99 (C-3), 54.56, 54.37 (C-2), 44.15, 43.96 20 
(CHCH2CH), 25.55, 25.46 (CH(CH3)2), 23.19, 23.16, 22.56, 22.41, 22.13, 21.90 (NHCOCH3 21 
and CH(CH3)2) 14.46, 14.41 (OCH2CH3) ppm. MS (ES+): m/z 571.21 [M+Na]
+ 22 
Methyl ((((2R,3S,4R,5S)-5-acetamido-3,4,6-trihydroxytetrahydro-2H-pyran-2-23 
yl)methoxy)(4-methoxyphenoxy)phosphoryl)-D-prolinate (8b): Prepared according to 24 
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Standard procedure 3 in 32 %, yield as a mixture of RP and SP diastereoisomers as  and  1 
anomers. Light yellow oil; 0.23 g. 31P-NMR (202 MHz, CDCl3): δP 2.36 (0.3P), 2.03 (1P), 1.90 2 
(0.4P) ppm. 1H-NMR (500 MHz, CDCl3): δH 7.13 (d, 2H, J = 9.0 Hz, CH-Ar), 6.89 (d, 2H, J = 3 
9.0 Hz, CH-Ar), 5.04 (m, 1H, H-1), 4.55-51 (m, 1H, NHCHCO), 4.33-4.31 (m), 4.26-4.23 (m), 4 
3.98-3.95 (m), 3.81-3.78 (m), 3.71 (s, 3H, COOCH3), 3.69 (s, 3H, PhOCH3), 3.41-3.33 (m), 5 
2.19-2.13 (m, 2H, CH2Pro), 1.99 (s, 3H, NHCOCH3), 1.96-1.81 (m, 2H, CH2Pro) ppm. 
13C-6 
NMR (125 MHz, MeOD): δC 174.38 (C=O ester), 172.77 (NHCOCH3), 156.94 (“ipso” 7 
PhOCH3), 144.15 (d, 
2JC-P= 2.5 Hz, “ipso” POPh), 120.93 (d, 
3JC-P= 4.6 Hz, CH-POPh), 120.67 8 
(d, 3JC-P= 4.5 Hz, CH-POPh), 120.66, 114.33, (CHAr), 93.66, 93.33 (C-1), 68.95, 68.82, 67.05, 9 
66.80, 60.87, 60.62, 54.68, 53.89, 51.34, 30.82 (d, 2JC-P= 9.1 Hz, CH2Pro), 24.81 (d, 
3JC-P= 9.0 10 
Hz, CH2Pro), 21.24 (NHCOCH3) ppm. MS (ES+): m/z 541.17 [M+Na]
+ 11 
Isopropyl ((((2R,3S,4R,5S)-5-acetamido-3,4,6-trihydroxytetrahydro-2H-pyran-2-12 
yl)methoxy)(4-methoxyphenoxy)phosphoryl)-L-alaninate (8c): Colorless oil; 42 %, 0.11 g. 31P 13 
NMR (202 MHz, CDCl3, mixture of RP and SP diastereoisomers as  and  anomers): δP 8.42 14 
(0.2P), 8.33 (0.8P), 8.10 (1P) ppm. 1H-NMR (500 MHz, CDCl3): δH 7.17-7.13 (m, 2H, CH-15 
Ar), 6.89-6.87 (m, 2H, CH-Ar), 5.03 (d, 1H, J = 9.0 Hz, H-1), 4.98-4.93 (m, 1H, CH(CH3)2), 16 
4.32-4.31 (m, 1H, H-2), 4.29-4.21 (m), 3.98-3.95 (m), 3.93-3.88 (m, 1H, NHCHCO), 3.80-3.77 17 
(m), 3.70 (s, 1.5H, PhOCH3), 3.69 (s, 1.5H, PhOCH3), 3.62-3.55 (m, 2H, H-6), 1.99 (s, 3H, 18 
NHCOCH3), 1.37-1.32 (m, 3H, NHCHCH3), 1.23-1.20 (m, 6H, CH(CH3)2) ppm. 
13C-NMR 19 
(125 MHz, MeOD): δC 173.49, 173.44 (C=O ester), 172.76, (NHCOCH3), 156.89 (“ipso” 20 
OPh), 144.38, 114.32 (“ipso” POPh), 121.01, 120.98, 114.21, 114.18 (CHAr), 93.79, 93.30 (C-21 
1), 73.11 (d, 4JC-P= 7.5 Hz, C-4), 73.08 (d, 
4JC-P= 6.3 Hz, C-4), 70.58, 70.37 (NHCHCO), 68.40, 22 
68.37 (C-5), 68.04 (d, 2JC-P= 5.3 Hz, C-6), 67.88 (d, 
2JC-P= 5.4 Hz, C-6), 62.27, 62.22 23 
(OCH2CH3), 56.02, 55.99 (C-3), 54.56, 54.37 (C-2), 44.15, 43.96 (CHCH2CH), 25.55, 25.46 24 
31 
 
(CH(CH3)2), 23.19, 23.16, 22.56, 22.41, 22.13, 21.90 (NHCOCH3 and CH(CH3)2) 14.46, 14.41 1 
(OCH2CH3) ppm. MS (ES+): m/z 543.18 [M+Na]
+ 2 
Synthesis of (3S,4R,5S,6R)-3-Acetamido-6-(hydroxymethyl)tetrahydro-2H-pyran-2,4,5-3 
triyl triacetate (11): N-acetyl-D-mannosamine (22.6 mmol, 5 g) was dissolved in pyridine (73 4 
mL) and trityl chloride (24.86 mmol, 6.93 g) was added to the mixture under argon atmosphere. 5 
The reaction mixture was stirred at 60 C and monitored by TLC. After two hours, the mixture 6 
was concentrated in vacuo and extracted with ethyl acetate (3 x 50 mL), washed with brine and 7 
dried with Na2SO4. The product 9 was used in the next step without any further purification. 8 
To a stirred suspension of compound 9 (22.6 mmol) in pyridine (15 mL), acetic anhydride (12 9 
mL) was added at 0 C under protected atmosphere. The reaction mixture was allowed to warm 10 
at rt and stirred for 12 h. The solvent was evaporated in vacuo, then the reaction crude was 11 
extracted with DCM (3 x 20 mL) and purified by column chromatography (EtOAc/hexane 12 
75:25). Compound 10 was isolated as light yellow powder; 65 %; 8.65 g. 1H-NMR (500 MHz, 13 
CDCl3, mixture of diastereoisomers of  and anomers, 1:0.3): δH 7.44-7.41 (m, 6H, Ph), 14 
7.32-7.29 (m, 6H, Ph), 7.25-7.22 (m, 3H, Ph), 6.11 (d, 0.7H, J = 1.9 Hz, NH), 5.85 (d, 0.3H, 15 
J = 1.7 Hz, NH), 5.81 (d, 0.3H, J = 9.1 Hz, H-1), 5.77 (d, 0.7H, J = 9.3 Hz, H-1), 5.36-5.25 16 
(m, 1H, H-4, 0.7H, H-3), 4.98 (dd, 0.3H, J = 3.9, 9.9 Hz, H-3), 4.76-4.73 (m, 0.3 H, H-2), 17 
4.64-4.61 (m, 0.7H, H-2), 3.92-3.89 (m, 0.7H, H-5), 3.70-3.64 (m, 0.3H, H-5), 3.38-3.33 18 
(m, 1H, H-6), 3.09 (dd, 0.3H, J = 4.1, 10.6 Hz, H-6), 3.05 (dd, 0.7H, J = 3.8, 10.6 Hz, H-6), 19 
2.16 (s, 2.1H, OCOCH3), 2.13 (s, 0.9H, OCOCH3), 2.11 (s, 0.9H, OCOCH3), 2.09 (s, 2.1H, 20 
OCOCH3), 1.99 (s, 2.1H, OCOCH3), 1.98 (s, 0.9H, OCOCH3), 1.78 (s, 0.9H, NHCOCH3), 21 
1.77 (s, 2.1H, NHCOCH3) ppm. Afterwards, a mixture of compound 10 (3.4 mmol, 2.0 g) in 22 
80% aqueous acetic acid (46 mL) was warmed up to 60 C and stirred for 4 h. Next, the reaction 23 
mixture was concentrated under vacuum and the resulting residue was purified by column 24 
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chromatography to give the expected compound 11. White powder; 75 %; 1.09 g. 1H-NMR 1 
(500 MHz, CD3OD, mixture of diastereoisomers of  and anomers, 1:0.3): δH 5.95 (d, 0.7H, 2 
J = 1.7 Hz, H-1), 5.92 (d, 0.3H, J = 1.7 Hz, H-1), 5.32 (t, 0.7H, J = 10.1 Hz, H-3), 5.27-5.24 3 
(m, 1H, H-4), 5.15-5.12 (m, 0.3H, H-3), 4.72-4.70 (m, 0.3H, H-2), 4.57-4.56 (m, 0.7H, H-4 
2), 3.92-3.88 (m, 0.7H, H-5), 3.72-3.60 (m, 0.3H, H-5, 2H, H-6), 2.16 (s, 2.1 H, OCOCH3), 5 
2.06-2.05 (m, 4.8H, 3 × OCOCH3), 2.03 (s, 2.1H, OCOCH3), 1.95 (s, 3H, NHCOCH3) ppm. 6 
Standard Procedure 4. General Synthesis of Phosphoramidates (12a-j): To a solution of 7 
compound 11 (1 equiv) in anhydrous THF was added tBuMgCl (1.5 equiv) at 0 C under argon 8 
atmosphere. After 30 min, a solution of an appropriate phosphorochloridates 3a-j (1.5 equiv) 9 
in dry THF was added dropwise to the mixture at the same temperature. Then, the reaction was 10 
allowed to reach room temperature and stirred for 12 h. The solvent was evaporated in vacuo 11 
and the crude residues were purified by column chromatography (DCM/CH3OH 98:2) to give 12 
compounds 12a-j as mixture of Sp and Rp diastereoisomers of  and  anomers. 13 
(3S,4R,5S,6R)-3-Acetamido-6-((((((S)-1-isopropoxy-1-oxopropan-2-14 
yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12a): 15 
Light yellow powder; 68%; 0.63 g. 31P-NMR (202 MHz, CD3OD, mixture of RP and SP 16 
diastereoisomers as  and  anomers): δP 3.83 (0.5P), 3.76 (1P), 3.55 (0.5P), 3.35 (0.2P) ppm.
 17 
1H-NMR (500 MHz, CD3OD): δH 7.40-7.37 (m, 2H, CH-Ph), 7.27-7.21 (m, 3H, CH-Ph), 6.00-18 
5.97 (m, 1H, H-1), 5.40-5.28 (m, 1.7H, H-3 and H-4), 5.20-5.18 (m, 0.3H, H-3), 5.04-4.97 (m, 19 
1H, CH(CH3)2), 4.77-4.76 (m, 0.3H, H-2), 4.61-4.60 (m, 0.7H, H-2), 4.35-4.13 (m, 3H, 2H-6 20 
and NHCHCO), 3.97-3.89 (m, 1H, H-5), 2.19-1.99 (m, 12H) (3 × OCOCH3 and NHCOCH3), 21 
1.39-1.34 (m, 3H, NHCHCH3), 1.28-1.24 (m, 6H, CH(CH3)2) ppm.
 13C-NMR (125 MHz, 22 
CD3OD): δC 173.22 (d, 
3JC-P= 5.2 Hz, C=O ester), 172.94 (d, 
3JC-P= 4.7 Hz, C=O ester), 172.44 23 
(d, 3JC-P= 4.7 Hz, C=O ester), 170.24 (d, 
3JC-P= 4.4 Hz, C=O ester), 170.15, 170.12, 170.05, 24 
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170.00, 168.71, 168.62, 168.60 (NHCOCH3 and OCOCH3), 150.81 (d, 
2JC-P= 7.0 Hz, “ipso” 1 
OPh), 129.39, 129.32, 124.75, 124.72, 120.19, 120.03 (CH-Ph), 91.75, 91.73, 90.72, 90.68 (C-2 
1), 71.37, 71.12 (NHCHCO), 69.31, 69.23 (C-3), 68.80, 68.75 (CH(CH3)2), 65.56, 65.49 (C-3 
6), 65.40,  65.31 (C-4), 50.38 (C-5), 49.13, 48.46 (C-2), 21.03, 20.99 (NHCOCH3), 20.62, 4 
20.58, 20.51 (CH(CH3)2), 19.32, 19.25 (OCOCH3), 19.02, 18.97 (NHCHCH3) ppm. HPLC: 5 
(gradient H2O/ACN from 90/10 to 0/100 in 30 min, flow: 1 mL/min,  = 210 nm): tR 21.29 6 
min, 21.70 min. MS (ES+): m/z 639.20 [M+Na]+ 7 
(3S,4R,5S,6R)-3-acetamido-6-((((((S)-1-ethoxy-4-methyl-1-oxopentan-2-8 
yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12b): 9 
Prepared according to Standard procedure 4 in 43 %, yield as a mixture of RP and SP 10 
diastereoisomers as  and  anomers. White powder; 360 mg. 31P-NMR (202 MHz, CD3OD): 11 
δP 3.81 (0.6P), 3.71 (1P), 3.65 (0.4P) ppm.
 1H-NMR (500 MHz, CD3OD): δH 7.38-7.34 (m, 2H, 12 
CH-Ph), 7.22-7.18 (m, 3H, CH-Ph), 5.97-5.96 (m, 1H, H-1), 5.40-5.16 (m, 1.8H, H-3 and H-13 
4), 5.20-5.16 (m, 0.2H, H-3), 4.75-4.74 (m, 0.2H, H-2), 4.58-4.57 (m, 0.8H, H-2), 4.33-4.01 14 
(m, 5H, H-6, OCH2CH3 and NHCHCO), 3.88-3.83 (m, 1H, H-5), 2.17-1.97 (m, 3 × OCOCH3 15 
and NHCOCH3), 1.75-1.58 (m, 1H, CH(CH3)2), 1.55-1.48 (m, CHCH2CH), 1.27-1.23 (q, 3H, 16 
J = 6.55 Hz, OCH2CH3), 0.93-0.82 (m, 6H, CH(CH3)2) ppm.
 13C-NMR (125 MHz, CD3OD): 17 
δC 175.52 (d, 
3JC-P= 2.9 Hz, C=O ester), 175.46 (d, 
3JC-P= 1.4 Hz, C=O ester), 175.19 (d, 
3JC-18 
P= 2.7 Hz, C=O ester), 173.81 (d, 
3JC-P= 4.4 Hz, C=O ester), 171.65, 171.59, 171.52, 171.39, 19 
171.36 (OCOCH3), 170.10, 169.97 (NHCOCH3), 152.25, 152.19, 152.16, 152.15 (“ipso” 20 
OPh), 130.78, 130.71, 130.67, 126.14, 126.10, 126.05, 121.59 (d, 3JC-P= 4.5 Hz, CH-Ph), 21 
121.28 (d, 3JC-P= 4.9 Hz, CH-Ph), 93.14, 93.11, 92.20, 92.17 (C-1), 72.88, 72.60, 70.69, 70.58 22 
(C-5, C-4, C-3), 66.93, 66.90 (OCH2CH3), 66.82 (C-2), 62.30 (d, 
2JC-P= 10.0 Hz, C-6), 54.60 23 
(d, 2JC-P= 4.9 Hz, NHCHCO), 50.52 (CH(CH3)2), 44.03 (d, 
3JC-P= 7.7 Hz, CHCH2CH), 25.57, 24 
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25.41, 23.26, 23.11, 22.39, 22.07, 21.71, 21.67, 20.72, 20.64, 14.47 (NHCOCH3, 3 ×OCOCH3, 1 
OCH2CH3, and CH(CH3)2) ppm. HPLC: (gradient H2O/ACN from 90/10 to 0/100 in 30 min, 2 
flow: 1 mL/min,  = 210 nm): tR 18.55 min, 18.96 min. MS (ES+): m/z 667.23 [M+Na]
+ 3 
(3S,4R,5S,6R)-3-acetamido-6-(((((R)-2-(methoxycarbonyl)pyrrolidin-1-4 
yl)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12c): 5 
Prepared according to Standard procedure 4 in 16 %, yield as a mixture of RP and SP 6 
diastereoisomers as  and  anomers. White powder; 0.12 g. 31P-NMR (202 MHz, CD3OD) δP 7 
1.75 (1P), 1.65 (0.4P), 1.32 (0.6P), 1.23 (0.1P) ppm. 1H-NMR (500 MHz, CD3OD): δH 7.39-8 
7.35 (m, 2H, CH-Ph), 7.28-7.19 (m, 3H, CH-Ph), 5.98 (d, 0.3H, J = 1.9 Hz, H-1), 5.97 (d, 0.7H, 9 
J = 1.8 Hz, H-1), 5.37-5.26 (m, 1.7H, H-3 and H-4), 5.24-5.16 (m, 0.3H, H-3), 4.75-4.74 (m, 10 
0.3H, H-2), 4.60-4.58 (m, 0.7H, H-2), 4.41-4.10 (m, 4H, NHCHCO, H-5 and 2H-6), 3.72 (s, 11 
0.9H, OCH3), 3.68 (s, 2.1H, OCH3), 3.40-3.37 (m, 2H, H-Pro), 2.21-1.87 (m, 16H, 4H-Pro, 3 12 
× OCOCH3 and NHCOCH3) ppm.
 13C-NMR (125 MHz, CD3OD): δC 174.30, 174.08, 172.93, 13 
172.30 (C=O ester), 170.27, 170.22, 170.11, 170.01, 169.97, 169.93, 168.69, 168.60, 168.58 14 
(NHCOCH3 and OCOCH3), 150.73 (d, 
2JC-P= 7.1 Hz, “ipso” OPh), 150.59 (d, 
2JC-P= 7.4 Hz, 15 
“ipso” OPh), 129.51, 129.44, 124.85, 124.82, 124.76, 119.99, 119.96, 119.85, 119.81 (CH-Ph), 16 
91.84, 91.77, 90.77, 90.62 (C-1), 71.34, 71.24, 71.19 (C-5), 69.31, 69.26 (C-3), 65.55 (d, 2JC-17 
P= 5.5 Hz, C-6), 65.35, 65.27, 65.17 (C-4), 60.63 (
2JC-P= 6.9 Hz, NHCHCO), 60.35 (
2JC-P= 6.3 18 
Hz) (NHCHCO), 51.41, 51.37 (COOCH3), 49.18, 49.12 (C-2), 47.35, 47.31 (NCH2CH2, 19 
overlap with the solvent), 30.95, 30.87, 30.80, 30.72 (NCH2CH2), 24.87, 24.79, 24.72 20 
(NCHCH2), 21.02, 20.99 (NHCOCH3), 19.32, 19.30, 19.29, 19.27, 19.24, 19.23 (OCOCH3) 21 
ppm. HPLC: (gradient H2O/ACN from 90/10 to 0/100 in 30 min, flow: 1 mL/min,  = 210 22 
nm): tR 15.80 min. MS (ES+): m/z 637.19 [M+Na]
+ 23 
(3S,4R,5S,6R)-3-acetamido-6-(((((2-methoxy-2-oxoethyl)amino)(naphthalen-1-24 
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yloxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12d): Prepared 1 
according to Standard procedure 4 in 49 %, yield as a mixture of RP and SP diastereoisomers 2 
as  and  anomers. Yellow powder; 0.53 g. 31P-NMR (202 MHz, CD3OD): δP 5.57 (0.9P), 3 
5.52 (0.4P), 4.75 (1P), 4.60 (0.3P) ppm. 1H-NMR (500 MHz, CD3OD): δH 8.20-8.17 (m, 1H, 4 
Naph), 7.89 (d, 1H, J = 8.0 Hz, Naph), 7.71 (d, 1H, J = 8.0 Hz, Naph), 7.59-7.43 (m, 4H, 5 
Naph), 6.00 (d, 0.8H, J = 1.7 Hz, H-1), 5.97 (d, 0.2H, J = 1.7 Hz, H-1), 5.40-5.28 (m, 1.8H, H-6 
3 and H-4), 5.21-5.16 (m, 0.2H, H-3), 4.75 (ddd, 0.2H, J = 1.9, 4.4, 9.6 Hz, H-2), 4.59 (ddd, 7 
0.8H, J = 1.9, 4.4, 9.6 Hz, H-2), 4.45-4.25 (m, 2H, H-6), 4.19-4.14 (m, 0.8H, H-5), 4.05-4.02 8 
(m, 0.1H, H-5), 3.97-3.93 (m, 0.1H, H-5), 3.97-3.93 (m, 2H, NHCH2CO), 3.69-3.67 (m, 3H, 9 
COOCH3), 2.15-1.96 (m, 12H, 3 × OCOCH3 and NHCOCH3) ppm.
 13C-NMR (125 MHz, 10 
CD3OD): δC 174.43 (C=O ester) 170.22, 170.08, 168.78, 168.65, 168.61 (NHCOCH3 and 11 
OCOCH3), 146.51, 134.91, 127.86 (“ipso” ONaph, Naph-C10 and Naph-C9), 127.43, 126.36, 12 
126.11, 125.23, 124.60, 121.46 (Naph), 121.35 (d, 3JC-P= 6.9 Hz, Naph-C1), 115.07 (d, 
3JC-P= 13 
3.9 Hz, Naph-C1), 114.95 (d, 3JC-P= 3.3 Hz, Naph-C1), 91.79, 91.73, 90.71 (C-1), 71.30 (
3JC-14 
P= 6.4 Hz, C-5), 71.22 (
3JC-P= 6.4 Hz, C-5), 71.12 (C-5), 69.21 (C-3), 65.63 (d, 
2JC-P= 5.3 Hz, 15 
C-6), 65.50 (d, 3JC-P= 5.7 Hz, C-6), 65.29 – 65.27 (C-4), 51.26 (OCH3), 49.18 (C-2), 42.39, 16 
42.33, 42.26 (NHCH2CO), 21.00, 20.97 (NHCOCH3), 19.28, 19.25 (OCOCH3) ppm. HPLC: 17 
(gradient H2O/ACN from 90/10 to 0/100 in 30 min, flow: 1 mL/min,  = 210 nm): tR 20.19 18 
min, 20.77 min. MS (ES+): m/z 647.17 [M+Na]+ 19 
(3S,4R,5S,6R)-3-acetamido-6-((((((S)-1-ethoxy-1-oxo-3-phenylpropan-2-20 
yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12e): 21 
Prepared according to Standard procedure 4 in 45 %, yield as a mixture of RP and SP 22 
diastereoisomers as  and  anomers. Yellow powder; 0.53 g.  31P-NMR (202 MHz, CD3OD): 23 
δP 3.40 (1P), 3.21 (0.3P), 3.02 (0.1P) ppm. 
1H-NMR (500 MHz, CD3OD): δH 7.33-7.15 (m, 24 
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8H, CH-Ar), 7.11, 7.05 (m, 2H, CH-Ar), 5.96 (d, 1H, J = 1.7 Hz, H-1), 5.93 (d, 1H, J = 1.7 Hz, 1 
H-1), 5.33-5.14 (2H, m, H-3 and H-4), 4.74-4.02 (m, 6H, H-5 and 2H-6 and OCH2CH3 and 2 
NHCHCO), 3.05-3.01 (m, 1H, CHCH2Ph), 2.95-2.91 (m, 1H, CHCH2Ph), 2.15-1.96 (m, 12H, 3 
3 × OCOCH3 and NHCOCH3), 1.19-1.15 (m, OCH2CH3) ppm.
 13C-NMR (125 MHz, CD3OD): 4 
δC 174.26, 174.05, 173.80, 171.64, 171.59, 171.46, 171.320, 170.08, 170.01 (C=O ester, 5 
NHCOCH3 and 3 × OCOCH3), 152.04 (d, 
2JC-P= 6.2 Hz, “ipso” OPh), 137.95 (“ipso” CH2Ph), 6 
130.73, 130.69, 130.55, 129.50, 127.96, 127.90, 127.90, 126.06, 121.40, 121.38, 121.35 (CH-7 
Ar), 93.13, 92.16, 92.05 (C-1), 72.72, 72.61, 72.44 (d, 2JC-P= 6.3 Hz, NHCHCO), 70.71, 70.63 8 
(C-3), 66.70 (C-4), 66.65 (d, 2JC-P= 5.5 Hz, C-6), 66.45 (d, 
2JC-P= 5.4 Hz, C-6), 62.41, 62.33 9 
(OCH2CH3), 57.80, 57.79, 57.70 (C-5), 50.74, 50.67, 50.52 (C-2), 22.39, 22.36 (NHCOCH3), 10 
20.70, 20.64, 20.62 (OCOCH3), 14.36 (d, J = 3.8 Hz, OCH2CH3) ppm. HPLC: (gradient 11 
H2O/ACN from 90/10 to 0/100 in 30 min, flow: 1 mL/min,  = 210 nm): tR 23.11 min, 23.44 12 
min, 23.79 min, 24.23 min. MS (ES+): m/z 701.21 [M+Na]+ 13 
(3S,4R,5S,6R)-3-acetamido-6-((((((S)-1-(benzyloxy)-1-oxopropan-2-yl)amino)(naphthalen-14 
1-yloxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12f): Prepared 15 
according to Standard procedure 4 in 47 %, yield as a mixture of RP and SP diastereoisomers 16 
as  and  anomers. Yellow powder; 0.58 g. 31P-NMR (202 MHz, CD3OD): δP 4.11 (1P), 3.81 17 
(0.8P), 3.52 (0.2P) ppm. 1H-NMR (500 MHz, CD3OD): δH 8.24-7.24 (12H, m, CH-Ar), 6.03 18 
(d, 1H J = 1.6 Hz, H-1), 6.00 (d, 1H, J = 1.6 Hz, H-1), 5.98 (d, 1H, J = 1.6 Hz, H-1), 5.96 (d, 19 
1H, J = 1.6 Hz, H-1), 5.50-5.17 (m, 2H, H-3 and H-4), 5.15-5.04 (m, 2H, CH2Ph), 4.78-4.61 20 
(m, 1H, H-2), 4.44-3.90 (m, 4H, H-5 and 2H-6 and NHCH), 1.17-1.95 (12H, m, 3 × OCOCH3 21 
and NHCOCH3), 1.37 (3H, dd, J = 18.7, 7.4 Hz, CHCH3) ppm.
 13C-NMR (125 MHz, CD3OD): 22 
δC 174.99, 174.85, 173.87, 173.81 (C=O ester), 171.63, 171.51, 171.45, 171.38, 170.04, 170.00 23 
(NHCOCH3 and OCOCH3), 147.98, 147.93 (“ipso” Naph), 137.19, 136.26, 129.54, 129.27, 24 
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129.17, 128.88 , 127.90  127.73, 127.51, 127.46, 126.59, 125.95, 125.91, 122.85, 122.78, 1 
116.42 (CH-Ar), 93.13, 92.17, 92.09 (C-1), 66.80, 66.65 (C-4), 51.90, 51.76 (C-5), 50.63, 2 
50.51 (C-2), 22.63 (NHCOCH3), 20.68, 20.64 (OCOCH3), 20.31, 20.25 ppm. HPLC: (gradient 3 
H2O/ACN from 90/10 to 0/100 in 30 min, flow: 1 mL/min,  = 210 nm): tR 25.20 min, 25.45 4 
min, 25.39 min, 26.25 min. MS (ES+): m/z 737.23 [M+Na]+ 5 
(3S,4R,5S,6R)-3-acetamido-6-((((((S)-1-(benzyloxy)-3-methyl-1-oxobutan-2-6 
yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12g): 7 
Prepared according to Standard procedure 4 in 40 %, yield as a mixture of RP and SP 8 
diastereoisomers as  and  anomers. Yellow powder; 0.39 g. 31P-NMR (202 MHz, CD3OD): 9 
δP 4.30 (1P), 4.14 (0.2P), 3.96 (0.1P) ppm.
 1H-NMR (500 MHz, CD3OD): δH 7.41-7.33 (m, 7H, 10 
CH-Ar), 7.25-7.17 (m, 3H, CH-Ar), 6.00 (d, 0.5H, J = 1.5 Hz, H-1), 5.97 (d, 0.5H, J = 1.7 Hz, 11 
H-1), 5.38-5.26 (m, 1.7H, H-4 and H-3), 5.23-5.14 (m, 2.3H, OCH2Ph and H-3), 4.80-4.77 (m, 12 
0.3H, H-2), 4.63-4.61 (m, 0.7H, H-2), 4.24-4.19 (m, 2H, H-6), 4.16-4.14 (m, 0.7H, H-5), 3.94-13 
3.91 (m, 0.3H, H-5), 3.78-3.74 (m, 0.3H, NHCHCO), 3.73-3.69 (m, 0.7H, NHCHCO), 2.17-14 
1.99 (m, 13H, 3 × OCOCH3, CH(CH3)2 and NHCOCH3), 0.93-0.87 (m, 6H, CH(CH3)2) ppm.
 15 
13C-NMR (125 MHz, CD3OD): δC 172.85, 172.69, 172.41, 172.37 (C=O ester), 170.29, 170.22, 16 
170.12, 170.09, 170.05, 170.01, 168.71, 168.65, 168.61 (NHCOCH3 and OCOCH3), 150.80 17 
(d, 2JC-P= 7.1 Hz, (“ipso” OPh), 150.77 (d, 
2JC-P= 7.1 Hz, “ipso” OPh), 135.81, 135.77 (“ipso” 18 
OCH2Ph), 129.41, 129.37, 129.33, 128.26, 128.23, 128.20, 128.16, 128.11, 128.06, 124.73, 19 
124.71, 120.25, 120.22, 120.19, 120.09, 120.05, 120.02, 119.99 (CH-Ar), 91.75, 90.82 (C-1), 20 
73.77, 73.65, 71.39, 71.25, 71.22, 71.17, 69.32, 69.23 (C-3 and C-5), 66.65, 66.60, 66.50 21 
(OCH2Ph), 65.63 (d, 
2JC-P= 5.7 Hz, C-6), 65.44, 65.41 (C-4), 60.66 (d, 
2JC-P= 7.6 Hz, 22 
NHCHCO), 60.49 (d, 2JC-P= 5.1 Hz, NHCHCO), 49.41, 49.34, 49.27, 49.16 (C-2), 31.79 (d, 23 
3JC-P= 7.4 Hz, CH(CH3)2), 31.70 (d, 
3JC-P= 7.4 Hz, CH(CH3)2), 21.16, 21.11, 19.43, 19.35 24 
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(NHCOCH3 and OCOCH3), 18.17, 17.14 (CH(CH3)2) ppm. HPLC: (gradient H2O/ACN from 1 
90/10 to 0/100 in 30 min, flow: 1 mL/min,  = 210 nm): tR 25.23 min, 25.49 min, 25.90 min. 2 
MS (ES+): m/z 715.24 [M+Na]+ 3 
(3S,4R,5S,6R)-3-acetamido-6-((((((2S,3S)-1-ethoxy-3-methyl-1-oxopentan-2-4 
yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12h): 5 
Prepared according to Standard procedure 4 in 64 %, yield as a mixture of RP and SP 6 
diastereoisomers as  and  anomers. Yellow powder; 0.12 g. 31P-NMR (202 MHz, CD3OD): 7 
δP 4.22 (1P), 4.16 (0.2P) ppm.
 1H-NMR (500 MHz, CD3OD): δH 7.38-7.35 (m, 2H, CH-Ar), 8 
7.24-7.18 (m, 3H, CH-Ar), 5.97 (d, 0.8H, J = 2.1 Hz, H-1), 5.95 (d, 0.2H, J = 1.9 Hz, H-1), 9 
5.36-5.16 (m, 2H, H-4 and H-3), 4.76-4.74 (m, 0.2H, H-2), 4.59-4.58 (m, 0.8H, H-2), 4.21-10 
4.06 (m, 5H, H-6, H-5 and OCH2CH3), 3.75-3.68 (m, 1H, NHCHCO), 2.18-1.97 (m, 12H, 3 × 11 
OCOCH3 and NHCOCH3), 1.80-1.74 (m, 1H, CH3CHCH2), 1.57-1.43 (m, 1H, CHCH2CH3), 12 
1.27-1.21 (m, 4H, OCH2CH3 and CHCH2CH3), 0.92-0.85 (m, 6H, CH3CHCH2 and 13 
CHCH2CH3) ppm.
 13C-NMR (125 MHz, CD3OD): δC 173.00 (d, 
3JC-P= 3.3 Hz, C=O ester), 14 
172.88 (d, 3JC-P= 3.3 Hz, C=O ester), 172.82 (d, 
3JC-P= 3.3 Hz, C=O ester), 172.43 (d, 
3JC-P= 15 
4.0 Hz, C=O ester), 170.27, 170.21, 170.15, 170.08, 170.02, 169.99, 168.66, 168.59, 168.56 16 
(NHCOCH3 and OCOCH3), 150.82 (d, 
2JC-P= 6.7 Hz, “ipso” OPh), 150.80 (d, 
2JC-P= 7.4 Hz, 17 
“ipso” OPh), 129.38, 129.33, 124.74, 124.68, 120.17 (d, 3JC-P= 4.5 Hz, CHPh), 120.01 (d, 
3JC-18 
P= 4.6 Hz, CHPh), 119.94 (d, 
3JC-P= 4.7 Hz, CHPh), 91.72, 90.77 (C-1), 71.18 (d, 
3JC-P= 6.9 19 
Hz, C-5), 69.29, 69.19 (C-3), 65.56, 65.52 (OCH2CH3), 65.39 (C-4), 60.86, 60.77 (C-6), 59.35 20 
(NHCHCO), 49.14 (C-2), 38.50, 38.43 (CH3CHCH2), 24.67, 24.62, 24.48 (CHCH2CH3), 21 
21.01, 19.34, 19.29, 19.26 (NHCOCH3 and OCOCH3), 14.51, 14.41 (CH3CHCH2), 13.14 22 
(OCH2CH3), 10.25, 10.17 (CHCH2CH3) ppm. HPLC: (gradient H2O/ACN from 90/10 to 0/100 23 
in 30 min, flow: 1 mL/min,  = 210 nm): tR 17.36 min, 17.90 min, 18.32 min. MS (ES+): m/z 24 
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667.23 [M+Na]+ 1 
(3S,4R,5S,6R)-3-acetamido-6-(((((1-(benzyloxy)-2-methyl-1-oxopropan-2-2 
yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12i): 3 
Prepared according to Standard procedure 4 in 34 %, yield as a mixture of RP and SP 4 
diastereoisomers as  and  anomers. Yellow powder; 0.07 g. 31P-NMR (202 MHz, CD3OD): 5 
δP 2.20 (1P), 1.89 (0.4P), 1.77 (0.1P) ppm. 
1H-NMR (500 MHz, CD3OD): δH 7.39-7.29 (m, 6 
7H, CH-Ar), 7.22-7.15 (m, 3H, CH-Ar), 5.97 (d, J = 1.6 Hz, 0.8H, H-1), 5.94-5.93 (0.2H, H-7 
1), 5.35-5.23 (m, 1.8H, H-4 and H-3), 5.22-5.11 (m, 2.2H, OCH2Ph and H-3), 4.78-4.75 (m, 8 
0.2H, H-2), 4.60-4.58 (m, 0.8H, H-2), 4.27-4.15 (m, 2H, H-6), 4.13-4.09 (m, 0.8H, H-5), 3.95-9 
3.91 (m, 0.1H, H-5), 3.90-3.86 (m, 0.1H, H-5), 2.13-1.96 (m, 12H, 3 × OCOCH3 and 10 
NHCOCH3), 1.52-1.44 (m, 6H, CH3CCH3) ppm.
 13C-NMR (125 MHz, CD3OD): δC 176.44 (d, 11 
3JC-P= 3.4 Hz, C=O ester), 176.62 (d, 
3JC-P= 3.5 Hz, C=O ester), 174.35, 174.27, 174.80, 171.64, 12 
171.57, 171.49, 171.46, 171.31, 170.06, 169.99 (NHCOCH3 and OCOCH3), 152.23 (d, 
2JC-P= 13 
7.0 Hz, “ipso” OPh), 137.38 (d, 2JC-P= 7.0 Hz, “ipso” OCH2Ph), 130.73, 130.69, 129.57, 14 
129.26, 129.18, 126.02, 121.57, 121.52, 121.49, 121.46 (CHAr), 93.13, 93.08, 92.15, 92.09 15 
(C-1), 75.14 (d, 3JC-P= 7.5 Hz, C-5), 74.91 (d, 
3JC-P= 7.6 Hz, C-5), 72.57, 72.50, 70.78, 70.56 16 
(C-3), 68.24, 68.22 (OCH2Ph), 66.83 (C-4), 66.70 (d, 
2JC-P= 5.6 Hz, C-6), 50.79, 50.68, 50.54, 17 
50.51 (C-2), 27.63, 27.59, 27.53, 27.48, 27.34, 27.30, 27.20, 27.16 (CH3CCH3), 22.42, 22.39, 18 
20.73, 20.69, 20.66 (NHCOCH3 and OCOCH3) ppm. HPLC: (gradient H2O/ACN from 90/10 19 
to 0/100 in 30 min, flow: 1 mL/min,  = 210 nm): tR 18.23 min, 18.57 min. MS (ES+): m/z 20 
701.22 [M+Na]+ 21 
(3S,4R,5S,6R)-3-acetamido-6-((((((S)-1-(benzyloxy)-4-methyl-1-oxopentan-2-22 
yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (12j): 23 
Prepared according to Standard procedure 4 in 61 %, yield as a mixture of RP and SP 24 
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diastereoisomers as  and  anomers. Light yellow powder; 0.37 g. 31P-NMR (202 MHz, 1 
CD3OD): δP 3.73 (0.5P), 3.68 (1P), 3.57 (0.4P) ppm.
 1H-NMR (500 MHz, CD3OD): δH 7.37-2 
7.31 (m, 7H, CH-Ar), 7.20-7.17 (m, 3H, CH-Ar), 5.97-5.96 (m, 0.7H, H-1), 5.94-5.93 (m, 0.3H, 3 
H-1), 5.35-5.12 (m, 4H, H-3, H-4 and OCH2Ph), 4.58-4.57 (m, 1H, H-2), 4.20-4.10 (m, 3H, H-4 
6 and H-5), 3.94-3.89 (m, 1H, NHCHCO), 2.16-1.97 (m, 12H, 3 × OCOCH3 and NHCOCH3), 5 
1.73-1.65 (m, 1H, CH(CH3)2), 1.49-1.46 (m, 2H, CHCH2CH), 1.56-1.49 (m, 6H, CH(CH3)2) 6 
ppm. 13C-NMR (125 MHz, CD3OD): δC 173.82, 173.79, 171.65, 171.59 (C=O ester), 171.36, 7 
169.98, (OCOCH3 and NHCOCH3), 152.12 (d, 
2JC-P= 6.5 Hz, “ipso” OPh), 137.13 (“ipso” 8 
OCH2Ph), 130.76, 130.67, 129.54, 129.40, 129.32, 129.27, 126.06, 126.01 (CH-Ar), 121.56 9 
(d, 3JC-P= 4.6 Hz, CH-Ar), 121.25 (d, 
3JC-P= 4.8 Hz, CH-Ar), 93.10, 93.07, 92.15 (C-1), 72.53, 10 
72.48 (C-5), 70.66, 70.55 (C-3), 67.94, 67.85 (OCH2Ph), 67.91 (d, 
2JC-P= 10.0 Hz, C-6), 66.72, 11 
66.70 (C-4,), 54.66, 54.60 (NHCHCO), 50.64, 50.48 (C-2), 43.87 (d, 3JC-P= 7.9 Hz, 12 
CHCH2CH), 43.72 (d, 
3JC-P= 7.6 Hz, CHCH2CH), 25.50, 25.36 (CH(CH3)2), 23.14, 23.03, 13 
22.39, 22.34, 22.04, 22.01 21.69, 20.69, 20.63, 20.60 (NHCOCH3, 3 ×OCOCH3 and 14 
CH(CH3)2) ppm. MS (ES+): m/z 729.25 [M+Na]
+ 15 
Triethyl ammonium ((2R,3S,4R,5S)-5-acetamido-3,4,6-triacetoxytetrahydro-2H-pyran-2-16 
yl)methyl ((S)-1-carboxy-3-methylbutyl)phosphoramidate (13): Prepared according to the 17 
Standard procedure 3. Light yellow powder; 47%; 0.37 g. 31P-NMR (202 MHz, CD3OD, 18 
mixture  and  anomers): δP 6.53 (1P), 6.41 (0.3P) ppm.
 1H-NMR (500 MHz, CD3OD): δH 19 
5.93-5.90 (m, 1H, H-1), 529.-5.16 (m, 2H, H-3 and H-4), 4.53-4.52 (m, 1H, H-2, overlap with 20 
the solvent), 4.11-4.10 (m, 1H, NHCHCO), 3.91-3.61 (m, 3H, H-6 and H-5), 3.12 (q, 6H, J = 21 
7.4 Hz, N(CH2CH3)3), 2.13-1.95 (m, 12H, 3 × OCOCH3 and NHCOCH3), 1.70-1.61 (m, 1H, 22 
CH(CH3)2), 1.47-1.44 (m, 2H, CHCH2CH), 1.20 (t, 9H, J = 7.3 Hz, N(CH2CH3)3), 0.88-0.83 23 
(m, 6H, CH(CH3)2) ppm.
 13C-NMR (125 MHz, CD3OD): δC 174.63, (C=O ester), 172.98, 24 
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172.78, 171.72, 171.54 (OCOCH3 and NHCOCH3), 91.97, 90.91 (C-1), 70.98, 70.92 1 
(NHCHCO), 70.07, 70.02 (C-3), 65.48, (C-4), 62.37 (d, 2JC-P= 4.6 Hz, C-6), 53.41 (C-5), 49.15, 2 
49.11 (C-2), 46.65 (N(CH2CH3)3), 42.93 (d, 
3JC-P= 3.4 Hz, CHCH2CH), 24.11 (CH(CH3)2), 3 
22.04, 21.94, 21.68, 21.37, 21.31, 20.85, 20.24, 20.22, 20.13 (NHCOCH3, 3 ×OCOCH3 and 4 
CH(CH3)2), 8.20 (N(CH2CH3)3)  ppm. LC-MS: (gradient H2O/ACN from 90/10 to 0/100 in 30 5 
min, flow: 1 mL/min): tR 2.5 min, 3.7 min. MS (ES-): m/z 574.16 [M-H]
- 6 
Enzymatic Activation Studies: All phosphoramidates 12a-i were analyzed for the enzymatic 7 
activation in the presence of carboxypeptidase Y. To a solution of compound 12a-i (5 mg) in 8 
[D6]acetone (150 L),was added 0.05M Trizma buffer (pH=7.6, 300 L) and 
31P-NMR was 9 
recorded at 25 C. A thawed solution of carboxypeptidase Y (0.1 mg in 150 L of 0.05M 10 
Trizma buffer) was added to the NMR sample and further analyzed by 31P-NMR at 25 C. 11 
Afterwards, spectra were recorded every 3 hours and the resulting data were processed and 12 
analyzed with Bruker Topspin 3.5 program and the estimated half-life was calculated. All 13 
processed compounds were analyzed by mass and all active species were detected. 14 
Caco-2 Assay: Caco-2 cells purchased from ATCC were seeded onto polyethylene membranes 15 
(PET) in 96-well BD Insert plates at 1 x 105 cells/cm2 and refreshed medium every 4~5 days 16 
until to the 21st to 28th day for confluent cell monolayer formation. The transport buffer in the 17 
study was HBSS with 10 mM HEPES at pH 7.40±0.05. Test compound was tested at 2 μM in 18 
presence and absence of 10 μM GF120918 bi-directionally in duplicate. Digoxin was tested at 19 
10 μM in presence and absence of 10 μM GF120918 bi-directionally in duplicate, while nadolol 20 
and metoprolol were tested at 2 μM in absence of 10 μM GF120918 in A to B direction in 21 
duplicate. Final DMSO concentration was adjusted to less than 1%. The plate was incubated 22 
for 2 hours in CO2 incubator at 37±1°C, with 5% CO2 at saturated humidity without shaking. 23 
And all samples after mixed with acetonitrile containing internal standard were centrifuged at 24 
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4000 rpm for 10 min. Subsequently,100 µL supernatant solution was diluted with 100 µL 1 
distilled water for LC/MS/MS analysis. Concentrations of test and control compounds in 2 
starting solution, donor solution, and receiver solution were quantified by LC/MS/MS 3 
methodologies, using peak area ratio of analyte/internal standard. After transport assay, lucifer 4 
yellow rejection assay was applied to determine the Caco-2 cell monolayer integrity. 5 
The apparent permeability coefficient Papp (cm/s) was calculated using the equation: 6 
        Papp = (dCr/dt) x Vr / (A x C0) 7 
Where dCr/dt is the cumulative concentration of compound in the receiver chamber as a 8 
function of time (µM/s); Vr is the solution volume in the receiver chamber (0.075 mL on the 9 
apical side, 0.25 mL on the basolateral side); A is the surface area for the transport, i.e. 0.0804 10 
cm2 for the area of the monolayer; C0 is the initial concentration in the donor chamber (µM). 11 
The efflux ratio was calculated using the equation: 12 
        Efflux Ratio = Papp (BA) / Papp (AB) 13 
Percent recovery was calculated using the equation: 14 
       % Recovery = 100 x [(Vr x Cr) + (Vd x Cd)] / (Vd x C0) 15 
Where Vd is the volume in the donor chambers (0.075 mL on the apical side, 0.25 mL on the 16 
basolateral side); Cd and Cr are the final concentrations of transport compound in donor and 17 
receiver chambers, respectively. 18 
Kinetic Solubility: Test compounds (10 mM in DMSO 10 µL/well) were added into pH 7.4 19 
NaH2PO4 buffer (490 µL/well) in a 96-well plate. The final concentration of test compound 20 
and DMSO was 200 µM and 2%, respectively. Test solutions were then incubated on a shaker 21 
at the speed of 600 rpm at room temperature. After 24 hours, 200 µL of each of solubility 22 
solution was transferred into a new MultiScreen filter plate (polycarbonate membrane), filtered 23 
by Millipore vacuum manifold and the filtrate was collected as test sample. Test compound 24 
concentration was determined in the filtrate using a standard curve detected by HPLC-UV. 25 
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Plasma Stability: Pooled frozen plasma was thawed in a water bath at 37℃ prior to 1 
experiments.  Plasma was centrifuged at 4000 rpm for 5 min and clots were removed, if any. 2 
The pH was adjusted to 7.4 ± 0.1 if required. Compounds were prepared as 1 mM intermediate 3 
solution by diluting 10 µL of the stock solution with 90 µL DMSO; 1 mM intermediate of 4 
positive control Propantheline was prepared by diluting 10 µL of the stock solution with 90 µL 5 
ultra-pure water; 100 μM dosing solution was prepared by diluting 10 µL of the intermediate 6 
solution (1 mM) with 90 µL 45%MeOH/H2O. 196 µL of blank plasma was spiked with 4 μL 7 
of dosing solution (100 μM) to achieve 2 μM of the final concentration in duplicate and samples 8 
were incubated at 37℃ in a water bath. At each time point (0,10, 30, 60 and 120 min), 800 μL 9 
of stop solution (200 ng/mL tolbutamide and 200 ng/mL Labetalol in 50% ACN/MeOH) was 10 
added to precipitate protein and mixed thoroughly. Sample plates were then centrifuged at 11 
4,000 rpm for 10 min. An aliquot of supernatant (100 μL) was transferred from each well and 12 
mixed with 200 μL ultra-pure water. The samples were shaken at 800 rpm for about 10 min 13 
before submitting to LC-MS/MS analysis. 14 
The % remaining of test compound after incubation in plasma was calculated using following 15 
equation: % Remaining= 100 x (PAR at appointed incubation time / PAR at T0 time), where 16 
PAR is the peak area ratio of analyte versus internal standard (IS). The appointed incubation 17 
time points are T0 (0 min), Tn (n=0, 10, 30, 60, 120 min). 18 
Microsomal Stability: Human liver microsomes were purchased from BD and were prepared 19 
in solution at a final concentration of 0.5 mg protein/L in potassium phosphate buffer. The 20 
NADPH regenerating system was isocitric dehydrogenase at a final concentration of 1 unit/mL 21 
at incubation and the stop solution was cold ACN including 100 ng/mL Tolbutamide and 100 22 
ng/mL Labetalol as internal standard (IS). Added 10 μL of compound (from 10 µM working 23 
solution in buffer) or control to all plates (T0, T5, T10, T20, T30, T60, NCF60) except matrix 24 
blank. Dispensed 680 μL/well microsome solution to 96-well plate as reservoir according to 25 
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the plate map, then added 80 μL/well to every plate by Apricot and incubated the mixture of 1 
microsome solution and compound at 37℃ for about 10 min. NADPH regenerating system was 2 
then added. At each time point, 300 (μL/well) stop solution was added to terminate the reaction. 3 
Sampling plates are then shaken for approximately 10 min. and samples were centrifuged at 4 
4000 rpm for 20 min at 4℃. Transferred 100 μL supernatant to 96-well plate containing HPLC 5 
water and mixed for LC/MS/MS. 6 
Use equation of first order kinetics to calculate T1/2 and CLint(mic): 7 
 8 
 9 
 10 
 11 
Cell Culture: Lec3 CHO cells and GNEM patient-derived myoblast cells were cultured in 12 
FirmaLab Inc. Lec3 CHO cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) 13 
supplemented with 5% Fetal Bovine Serum (FBS) and 1% antibiotic agent. GNEM patient-14 
derived myoblasts were grown in Nutrient Mixture Ham’s F-10 supplemented with 20% FBS, 15 
1% antibiotic agent, and 0.5% chick embryo extract (Accurate Chemical). Both cell lines were 16 
detached from FBS prior to challenging them to compounds. Cells were incubated in a serum 17 
free medium with 13b, 13c, ManNAc or media only control at 37°C in an atmosphere of 5% 18 
CO2 for 48 hours. Cell viability was determined before and after 48-hour incubation time. 19 
Membrane protein fractions were extracted after the incubation period and sialic acid was 20 
measured in all fractions. All cell culture reagents were obtained from Thermo Fisher 21 
Scientific, except where otherwise indicated. 22 
Cell Viability Assay: All cells and compound mixtures were treated the same. Each sample 23 
was thoroughly mixed and a 1:2 dilution was made with Trypan Blue stain (Sigma Aldrich) 24 
(20 μL of cell sample and 20 μL of 0.4% Trypan Blue) in a tube. The mixture was gently mixed, 25 
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10 μL of the mixture was then applied to the edge of a haemocytometer counting chamber 1 
between the cover slip and chamber. The mixture was drawn into the chamber by capillary 2 
action. 3 
Cells were counted using a 10× objective. With the assumption that dead cells take up the stain 4 
while viable cells do not take up the stain, both viable (unstained) and dead (stained) cells were 5 
counted in each of the four corner quadrants. An average of these four readings was obtained 6 
and multiplied by 104 to obtain the number of viable cells per mL in the sample and doubled 7 
to account for the 1:2 dilution. Viability was calculated by taking percentage of viable cells 8 
over total number of cells (viable and dead). 9 
Sialic Acid Quantification Assay: Cell-compound samples were pelleted after viability for 10 
extracting membrane protein. The Mem-PER plus membrane Protein Extraction Kit (Thermo 11 
Fisher Scientific) was used for protein extraction. The Mem-PER system consists of three 12 
reagents: Cell Wash Solution, Solubilization Buffer, and Permeabilization Buffer. Cell pellets 13 
were washed twice in 600 uL Cell Wash Solution. Supernatant was discarded. 150 uL 14 
Permeabilization Buffer was added to each cell pellet and vortexed to obtain a homogeneous 15 
cell suspension. Cells were incubated for 10 minutes at 4°C, then centrifuged for 15 minutes at 16 
16,000 × g. Supernatant contained cytosolic proteins, this was a transferred to a new tube. 100 17 
uL Solubilization Buffer was added to cell pellets and were resuspended. Samples were 18 
incubated at 4°C for 30 minutes, then centrifuged at 16,000 × g for 15 minutes. Supernatant 19 
containing solubilized membrane and membrane-associated proteins were transferred to a new 20 
tube. This fraction was used for measuring sialic acid. 21 
Sialic acid concentration was measured with an enzymatic method using the EnzyChrom Sialic 22 
Acid Assay Kit (BioAssay Systems) on a Victor X3 plate reader (Perkin Elmer). Kit consists 23 
of 6 reagents: Assay Buffer, Enzyme, Dye Reagent, Hydrolysis Reagent, Neutralization 24 
Reagent and 10 mM Sialic Acid Standard. Sialic Acid Standard was diluted to make a standard 25 
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curve, curve points were treated as any other sample. Free and total sialic acid was measured 1 
for all samples. To measure total sialic acid, samples needed to be hydrolyzed. Samples were 2 
hydrolyzed by mixing 20 uL sample with 80 uL Hydrolysis reagent, this was incubated at 80°C 3 
for 60 minutes. 20 uL Neutralization reagent was added to mixture and briefly spun down to 4 
bring down volume. Sialic a3cid assay was done by preparing a working solution of 93 uL 5 
Assay buffer, 1 uL Dye reagent and 1 uL Enzyme for each sample. In a black 96-well plate, 10 6 
uL of each sample were added to their corresponding position. 90 uL of working solution were 7 
added to 10 uL of each sample and incubated at room temperature for 60 minutes. After 8 
incubation period, fluorescence was read at λex = 530 nm and λem = 585 nm. Sample readings 9 
were plotted against standard curve to determine sialic acid concentration. Hydrolyzed samples 10 
were multiplied by a factor of six to account for the dilution during the hydrolysis step. 11 
12 
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